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Abstract 
        Respiratory Syncytial Virus (RSV) infects more than 90% of children under two years of age. 
It is the number one leading cause of hospitalizations for infants and young children. Inpatients 
suffer from RSV-induced moderate to severe bronchiolitis of the lower respiratory tract. RSV 
pathology that includes mucus hypersecretion, airway obstruction, bronchiolitis, eosinophilia is 
driven by pathogenic immune responses. Activated CD4 T cells include T helper cells type 1 (Th1), 
Th2, Th17, and Treg. Th2 and Th17 responses are pathogenic in that they trigger 
peribronchioalveolar lymphocytic aggregates, augment mucus production and reduce viral 
clearance. Regulatory T cells (Treg)—defined as Foxp3+ CD4 T cells—can be further induced by 
infection to mitigate RSV immunopathology including pathogenic Th2 responses. Understanding 
how Treg cells are regulated may reveal potential targets to therapeutically alleviate RSV-induced 
immunopathology. A recent study demonstrated that Notch ligand—Delta-like 4 (Dll4) was up-
regulated to attenuate RSV pathology, and intracellular Notch signaling perturbs Treg cell stability 
in autoimmune disease. But the role of Notch ligand Dll4 in Treg cells in pulmonary infection is 
still elusive. In this dissertation, we will demonstrate 1) The role of Dll4 in Treg and 2) How Dll4 
regulates Treg during RSV infection. 
        The current dissertation demonstrates that Dll4 was up-regulated by RSV infection especially 
on CD11b+ pulmonary dendritic cells (DC). Using systemic Dll4 neutralization and a Dll4 
knockdown DC transfer model, we found that Dll4 enhanced Foxp3 expression and reduced RSV 
immunopathology. Dll4 promoted peripheral Treg cell differentiation, harnessed Treg cell effector 
function, and stabilized Treg from Th17-like identities in vitro and in vivo during RSV infection.  
 xii  
        Using an epigenetic enzyme PCR array, we found that Dll4 and Notch signaling enhanced 
the expression of a novel histone methyltransferase—SET and MYND domain containing protein 
3 (SMYD3) in vitro and in vivo during RSV infection. SMYD3 catalyzed Dll4-facilitated histone 
3 lysine 4 tri-methylation (H3K4me3) around the Foxp3 loci in induced Treg cells, and SMYD3 
differentially regulated Dll4-stimulated genes discovered by RNA-seq. Consistent with Dll4 
activation, SMYD3 sustained Treg cells promoted anti-inflammatory IL-10 expression and 
prevented IL-17A production from T cells to mitigate pathogenic cytokines and mucus production.  
        Collectively, the studies in this dissertation suggest that Notch and its ligand Dll4 augment 
immunomodulatory Treg cell programs to ameliorate RSV immunopathology in part through an 
epigenetic mechanism—SMYD3. The results presented herein lay the foundation for future 
therapeutics targeting pulmonary and other mucosal inflammatory diseases.  
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Chapter 1 Introduction 
1.1 Respiratory syncytial virus (RSV) infection  
        Viral respiratory tract infections accounted for approximately 1 in 5 hospital admission 
among infants in the United States. Common viruses are influenza, parainfluenza, rhinovirus (RV), 
and respiratory syncytial virus (RSV)1,2. RSV is the most ubiquitous infectious virus as it infects 
more than 90% of infants by age 2, and it’s the number one leading cause of infantile bronchiolitis 
worldwide. RSV is a single-stranded RNA virus that belongs to the Paramyxoviridae family and 
has a 10-gene genome. Humans are the only known host for RSV. The viral envelope contains 
three proteins: attachment glycoprotein (G), fusion glycoprotein (F) and small hydrophobic (SH) 
protein.  RSV-F and RSV-G proteins are the main virulence factors that mediate airway epithelial 
cells penetrations3. The clinical feature of RSV infection—multinucleated epithelial cells, or 
syncytia—is the result of RSV-F protein that enables cell-to-cell fusion4.  
        RSV mainly causes lower respiratory tract infections in children. A recent report from CDC 
showed that RSV induced on average 57,527 hospitalizations annually among children younger 
than 5 year-old in the US5. A retrospective review showed that RSV induced mortality for all ages 
combined has been approximately 30/100,000 humans from 1990-2000, with an annual average 
mortality of over 170,000 worldwide6. While RSV is detrimental in infants and young children, it 
is also dangerous for the elderly, adults with compromised immune systems and adults with 
chronic heart or lung diseases, including pneumonia, asthma, chronic obstructive pulmonary 
disease, and congestive heart failure to causes more than a hundred thousand of  hospitalizations 
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annually in the United States in adults older than 657. The common symptoms of RSV infections 
are: runny nose, a decrease in appetite, and sneezing, and the acute phase of infection usually leads 
to symptoms such as a wheezing cough that can be diagnosed as asthma but is non-responsive to 
typical atopic asthma treatments7. Clinical manifestations such as airway obstruction are driven by 
pathogenic immune responses but not by viral replication or virus cytotoxicity7. Moreover, there 
is no effective vaccine available. Hence, understanding the immune responses to protect us from 
RSV infection are critical for designing effective therapies. 
        The innate immune response during RSV infection was investigated using murine mouse 
models. After RSV entry into the airways, airway epithelial cells secrete pro-inflammatory 
mediators (e.g. TNF-a, type 1 interferon, CCL5, Thymic stromal lymphopoietin TSLP). The lung 
resident alveolar macrophages also secrete type 1 interferons to initiate antiviral responses within 
the first 2 days post infection (dpi). These cytokines further recruit NK cells, type 2 innate 
lymphoid cells (ILC2)8, polymorphoneuclear leukocytes (PMN) and eosinophils to produce more 
inflammatory cytokines including IFNg, IL-5, IL-13 and IL-4. Innate lymphoid cells (ILC2) is the 
major producer of IL-13 that initiates mucin production from the airway epithelial cells during 
RSV infection8.  Pulmonary DC, especially CD11b+ conventional DC (CD11b+ cDC), display a 
massive influx into the lung after RSV infection9. Pulmonary DCs (Both CD11b+ cDC and 
CD103+ DC) are able to sample RSV and migrate to draining lymph node to present RSV antigen 
to T cells9. DCs then prime adaptive immunity to become long-term effectors during later phase 
(6dpi~12dpi) of infection and post RSV infection.  
        RSV re-infection occurs often throughout life, suggesting that it failed to initiate effective 
adaptive immunity including B cell and T cell memory responses10,11. In a mouse model, T cells 
enhanced disease since primary signs of RSV pathology were reduced after CD4 and CD8 T cells 
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depletion12. CD4 T cells appears to trigger peribronchioalveolar lymphocytic aggregates and 
augment disease while decreasing viral load; while CD8 T cells cause RSV clearance and reduce 
eiosinophilia and bronchiolitis severity13–15. Intriguingly, while total depletion of CD4 T cells 
(mostly CD4 T helper cells) suggested that CD4 T cells drive RSV disease, recent work identifies 
that a small subset of CD4 T cells—namely, T regulatory (Treg) cells—could instead mitigate 
RSV immunopathology. The CD4 T cell subsets will be introduced in the next section.  
 
Figure 1.1 RSV-initiated innate and adaptive immune responses1 
 
  
                                               
1 This figure was created by Hung-An (Anna) Ting 
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1.2 CD4 T helper cells and the pathogenesis of RSV infection 
The CD4 T helper (Th) cells combat pathogens after antigen recognition by mounting an effective 
and precise immune response. A successful immune response requires a coordinated effort by 
discrete subtypes of Th cells, each group characterized by their cytokine profile. Th cells type 1 
(Th1) are characterized by Interferon-gamma (IFN-g) production that helps to combat intracellular 
pathogens. Th type 2 (Th2) cells are characterized by Interleukin(IL)-4 (IL-4), IL-5 and IL-13 
secretion to respond to parasitic infections and allergic responses. Th17 cells secrete IL-17A and 
IL-17F to combat extracellular pathogens. Th9 is a recently identified subset that secrete IL-9 in 
response to allergic reactions. The pro-inflammatory actions of these Th subsets can be tempered 
by CD4+ Treg cells. There are two types of Treg cells: nTreg cells are developed in the thymus; 
while iTreg cells are adaptively induced from matured CD4+ naïve T cells (nT). iTreg and different 
Th subsets are derived from naïve CD4 T cells (nT) by the biological process called CD4 T cells 
differentiation.  
 
 
 
 
Figure 1.2 CD4 T cells differentiation 2 
                                               
2 This figure was created by Hung-An (Anna) Ting 
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Naïve CD4 T cells could be primed by antigen presenting cells (APC). APC presents antigen-
bearing MHC class II and B7.1/B7.2 to bind to TCR/CD3 complex and CD28, respectively. 
MHCII-TCR and B7.1/CD28 are signals 1 and 2 to induce full activation of CD4 T cells. In 
addition to signals 1 and 2, the environmental cytokine mileau skews naïve T cells toward different 
Th subtypes. These Th cells acquire discrete molecular signatures (transcription factors) and 
effector functions (cytokine secretion). The role of CD4 Th cells and their effector cytokines in 
RSV immunopathogenesis had been well studied. We will discuss these findings in the following 
paragraphs. 
1.2.1 Th2 and type 2 cytokines: IL-4, IL-5, IL-13 
            In humans, RSV infection induces mucus production, eosinophilia, elevated IgE levels and 
airway hyperreactivity16–18, symptoms associated with Th2-mediated immune responses. Clinical 
data point out that an imbalanced cytokine production skewed towards an increased ratio of IL-4 
over IFNg, correlates with RSV immunopathogenesis in human infants19. Infants are more 
predisposed to Th2 responses than Th1 responses since they express higher levels of IL-4 receptor 
on their CD4 T cells following RSV stimulation when compared to adult20, while neonatal CD4 
cells produces less IFNg21. RSV infection elicits both Th1 and Th2 responses by distinct surface 
glycoproteins. Sensitization of mice with recombinant vaccinia viruses expressing RSV-G mount 
Th2-dominated responses, while vaccinia viruses expressing RSV-F mount Th122. 
            In a murine pre-clinical model, blockage of IL-4 and IL-5 mitigates the development of 
eosinophilia and airway hypersensitivity in primary RSV infection23, although the role of IL-4 is 
more questionable than that of IL-5 since IL-4 deficiency doesn’t affect eosinophilia in RSV-G 
bearing vaccinia virus infection24. IL-13 not only contributes to eosinophilia but also induces 
mucus hypersecretion to exacerbate RSV immunopathogenesis3,25,26. It is worth noting that type 2 
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cytokines are secreted from immune cells other than Th2, for example IL-4 from basophils27 and 
IL-13 from ILC2 cells during RSV infection8. Therefore, pathogenic type 2 responses are 
contributed not only from Th2 but other innate cells.  
  The magnitude of type 2 cytokines responses following RSV infection in mice appears to 
be dependent on the viral strain. The Line 19 and 2–20 strains of RSV induce significantly greater 
amounts of IL-13 in the lung than the A2 and Long strains, resulting in increased mucus production 
and airway hyperreactivity25,28. The present thesis consistently used Line 19.  
1.2.2 Th17 and IL-17 family 
        Clinical data showed that IL-17A is increased in the tracheal aspirates but not in nasal washes 
of RSV-infected infants29,30, indicating that IL-17A may play a more significant role in the lower 
respiratory tract rather than in the upper airways. Using experimental models of RSV infection, 
IL-17A is mostly produced from CD4 Th17 cells but not double negative T or gd T cells30. Unlike 
type 2 cytokines that start to be abundant in the lung from 4 to 6 dpi, IL-17A production peaked at 
8 dpi30. There are multiple reports investigating how IL-17A is regulated. Efficient lymph node 
priming31, IL-27 receptor signaling32, IL-13 and STAT133 impede IL-17A production from CD4 
T cells. The function of IL-17A in RSV infection is to diminish CD8+ T cell responses, and it also 
increases mucus hypersecretion in both murine models and human primary airway epithelial cells 
30,34,35.   
1.2.3 Th9 and IL-9 
        As a newly identified subset, recent studies find that IL-9 is increased in both human tracheal 
samples and mice bronchial alveolar lavage (BAL) fluid and lung during RSV infection36,37. 
Furthermore, human IL9 gene polymorphisms are associated with increased RSV disease 
severity38. Thus, the function of IL-9 in RSV infection need to be carefully elucidated. 
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1.2.4 Treg, IL-10 and TGF-b 
        Opposite to the pathogenic role of CD4 Th cells, an increasing body of literature demonstrates 
that a subset of CD4 T cells, namely Treg cells, ameliorate RSV immunopathogenesis. Treg was 
identified as Forkhead box p3 (Foxp3)+ CD4 T cells, and they were enriched and expanded in lung 
and BAL during RSV infection39,40. Deletion of Treg cells during or before RSV infection using 
Diphtheria toxin (DT) treatment in Foxp3-DTR mice or anti-CD25 antibody, resulted in an 
increased influx of NK, eosinophil, Th2, and CD8 T cells39–42. Also, the systemic depletion of Treg 
cells creates a pro-inflammatory environment that results in weight loss and mucus hypersecretion 
in the depleted mice. Thus, Treg is required to limit pulmonary inflammation and pathogenic Th2 
responses during RSV infection39,41,42. The Treg inhibitory molecules: Cytotoxic T lymphocyte 
antigen 4(CTLA-4)39 and GranzymeB (GzmB)42 are responsible to mitigate RSV 
immunopathology. But the pathway for Treg differentiation, the function of other inhibitory Treg 
markers, and the cytokine profile in Treg post RSV infection are still elusive.  
        IL-10 polymorphisms are associated with susceptibility to severe disease in infants43,44, 
although severe RSV-infected infants have variable IL-10 levels that correlate with post-
bronchiolitis wheeze45–47. In murine models, IL-10 is produced by the adaptive immune system48,49, 
mostly by CD4 T cells following RSV infection50. It is intriguing to note that IL-10 is not only 
produced by Foxp3+ Treg but also by Foxp3—-IFN-g+ Th1 cells during RSV infection. 
Accumulated evidences using IL-10 knockout, IL-10 neutralizing antibody and IL-10 receptor 
blockade all confirm that lack of IL-10 drives weight loss, airway hypersensitivity, more CD4 and 
CD8 effector cells, increased IL-17A+ Th17 cells and IFN-g+ Th1 cells, and decreased Treg cells 
compared to cells expressing IL-10 48,50,51. However, IL-10 depletion and Treg depletion don’t 
significantly affect RSV viral clearance40,48.  
  8 
        TGF-b,  an anti-inflammatory cytokine, is expressed more in human neonatal DC than in 
adult DC.  Following RSV infection in human cells, TGF-b suppresses IFN-g, IL-2, and IL-12p70 
production and elevates RSV viral titer cells52. Unlike IL-10 that is mainly produced by CD4 T 
cells, TGF-b is mainly produced by human epithelial cells that is induced by RSV non-structural 
protein NS1 53. The role of TGF-b on CD4 T cells and the mechanism in RSV pathogenesis is 
lacking in both murine models and humans.  
1.3 Notch signaling in CD4 T cells differentiation 
1.3.1 Canonical and non-canonical Notch signaling pathway activation 
        Notch is a highly conserved signaling pathway throughout the metazoan family. It was first 
discovered in Drosophila 54 where there was one Notch receptor and two ligands--Delta and 
Serrate55. In mammalian animals, there are 4 Notch receptors (Notch1, Notch2, Notch3, Notch4) 
and 5 different ligands (Delta-like ligand 1(Dll1), Dll3, Dll4, Jagged1(Jag1), Jag2). Notch 
receptors are present on the cell surface as heterodimeric transmembrane proteins.  The 
functionality of Notch receptor-ligand binding is context-dependent in many developmental 
processes. 
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      Notch receptor-ligand binding enables the matrix metalloproteases of the ADAM family access 
to the Notch receptor ‘S2’ cleavage site. The ‘S2’ cleavage enables further cleavage of Notch 
receptor at its intramembrane ‘S3’ site by the g-secretase complex. The g-secretase complex 
cleavage is the critical step for Notch signaling activation. Cleavage of Notch by the g-secretase 
complex results in the release of Notch intracellular domain (NICD). NICD can translocate into 
nucleus and interact with Recombining binding protein suppressor of hairless (RBP-Jk),  co-
activator Mastermind-like family (MAML1-3), and another co-activator, p300, to initiate Notch 
target genes transcription (eg Hes, Hey, Deltex). This is called the “non-canonical” Notch 
signaling described in Drosophila56,57. See Figure 1.3.  
 
Figure 1.3 Canonical Notch signaling primes CD4 T cells3 
         
         In mammals there is another canonical Notch activation pathway that is reported to 
cooperatively initiate signaling with other pathways, including NF-kB and TGF-b/Smad3 
pathways. In CD4 T cells, Dll1 and Dll4 prefer to activate Notch1 or Notch2 signaling to drive 
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NICD translocation and association with the NF-kB gene to affect Ifng expression that is RBP-Jk-
independent58,59; the crosstalk and cooperation between the TGF-b pathway and Notch are mainly 
demonstrated during epithelial-to-mesenchymal transition (EMT) in epithelial cells and during 
myogenic differentiation. In vitro and in vivo pull-down assay shows that overexpressed NICD 
directly associates with Smad3 to drive the Notch target genes--Hey1 and Jagged1 expression for 
EMT60 and Hes1 for myogenesis61. Recent reports reveal the cross-talk may happen in primary 
CD4 T cells also, as Notch DNA-binding protein RBP-Jk cooperatively activates Il9 and Foxp3 
with Smad3 in Th962 and iTreg differentiation63, respectively.  
Figure 1.4 Pathways that cooperative with Notch signaling 4 
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1.3.2 Notch signaling in mature T cell differentiation and function 
        Notch signaling is emerging as a regulator of CD8 T cell differentiation and effector function, 
despite the fact that the role of Notch in CD8 T cells differentiation is less known than it is in CD4 
T cell activation and differentiation.  Relatedly, Notch 1 directly regulates master transcription 
factor Eomesodermin (Eomes)64that is critical in IFN-g production and cytolytic effector 
functional molecule (Perforin and Granzyme B) expression65,66. Other studies further identify that 
Notch 2 and its ligand Dll1 support granzyme B and IFN-g expression   67,68.  
        Notch appears to be a key regulator and amplifier in CD4 T cell differentiation. In peripheral 
organs, naive CD4 T cells express Notch1 and Notch2 but little Notch3 and Notch469, as is also 
true in Treg cells70. Notch signaling regulates various stages of T cells lineage development and 
differentiation, including early stages of thymocyte development, as well as CD4 Th 
differentiation69,71.  In the priming stage of Th cell differentiation, Notch1 contributes to CD4 T 
cell activation by promoting CD25 expression, early activation marker CD69, IL-2 production, 
and Akt-GSK3b downstream of co-stimulatory molecule CD28 in vitro72,73. More recent work 
further substantiates that Notch ligand Dll4 on DC sensitizes antigen responses and augmented T 
cells activation by facilitating co-stimulation and glucose metabolism74.  
        The role of Notch signaling in Th1 and Th2 differentiation has been suggested to have a 
binary paradigm. Notch ligand DLL4 promotes Th1 differentiation while inhibiting Th2 
differentiation whereas the Jag1 ligand promotes Th2 differentiation 69,75. However, a recent study 
questions the paradigm that Notch can regulate multiple subsets of Th76. In Th1, Dll4 and Notch 
not only promote Th1 effector IFNg and  transcription factor T-bet expression in vitro69,76,77, but 
also Th1 responses in vivo. Intracellular Notch signaling and Notch3 inactivation prevents Th1 
mediated experimental autoimmune encephalomyelitis (EAE)77,78. Redundant Notch1 and Notch2 
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are required to promote IFN-g secretion in Leishmania major infection59. Thus, Notch facilitate 
Th1 differentiation and effector functions.  
        During Th2 cell differentiation, Jag1 and Notch promote Gata3 and Il4 expressionn by direct 
binding of RBP-Jk onto Il4 and Gata3 promoters32–34, while Dll4 has been reported to  suppress 
Il4, Il5, and Il13 gene expression 67,73. Dll4 inhibition exacerbates Th2 cell and type 2 cytokine 
secretion in cockroach antigen-induced allergic asthma83 and primary RSV infection82 in vivo. But 
in chronic allergic disease, DLL4 but not Jag1 supports Th2 memory cell expansion in Schistosoma 
mansoni (S. mansoni) infection84, and Dll4 also supports Th2 cytokine expression in a STAT5-
dependent manner in RSV-exacerbated allergic asthma85. These conflicting data suggest that 
Notch regulates Th2 differentiation and effector function in context-dependent manner.  
        Notch was reported to promote Th9 differentiation by the interaction between Smad3 and 
RBP-Jk to bind to the Il9 promoter86. But compared to their role in Th9 cell differentiation, the 
role of Notch in Th17 and IL-17A differentiation have been more extensively investigated. Our 
lab and other scientists show that RBP-Jk bind to the Il17a and Rorc promoters to directly affect 
the Th17 program in murine Th1787 and human Th17 cells88. Dll4 intracellular Notch activation 
both promote pathogenic Th17 cells to exacerbate EAE pathogenesis88,89 and pneumonitis post 
bone marrow transplantation90.  
        A new paradigm was proposed recently that Notch can serve as an amplifier for multiple Th 
lineages. Notch supports persistent Th1, Th2 and Th17 cell responses simultaneously in vitro and 
in vivo during Trichuris muris infection 76. Another independent study suggests that both Th1 and 
Th2 responses are dampened by intracellular Notch inactivation in CD4 cells to Cryptococcus 
neoformans infection91. These new results indicate that Notch signaling may not be skewing 
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signals but rather enhance co-activation of multiple Th differentiation pathways to serve as a Th 
differentiation amplifier. 
        The role of DLL4 and Notch signaling in Treg cells remains enigmatic. Jagged2 and specific 
receptors, Notch1 and Notch3, promote the Treg cell master transcription factor, Foxp3 expression 
and Treg cell survival 92–96, and RBP-Jk is reported to directly bind the Foxp3 promoter and 
cooperatively facilitate Foxp3 transcription with TGF-b/Smad396.  In contrast, inactivating Notch 
signaling after Foxp3 expression enhanced Treg cell numbers and promoted tolerance 70. Blockage 
of Notch receptors and Notch ligands expanded Foxp3+ T cell populations in vivo in experimental 
autoimmune encephalomyelitis (EAE), graft-versus-host disease (GvHD), and Type 1 diabetes 
(T1D) 97–100. Therefore, the role of Notch as supportive or inhibitory in Treg differentiation is still 
debatable. Also, the expression of Notch ligands and their role in Treg functions and in Treg cells 
resistance to inflammation during infection have not been well-defined.   
 
1.4 Regulatory T cells (Treg) differentiation, stability, and plasticity 
1.4.1 History of regulatory T cells discovery 
The concept that CD4 T cells contains a subset of “suppressor T cells” was prevalent in the 
1970s 101but came out of favor in the 1980s because the proposed soluble suppressor molecules 
were not found102. The re-emergence of this concept started in 1997 when scurfy mice that had 
X-chromosome linked autoimmunity (ruffled skin, reddened eyes, enlargement of spleen and 
lymph nodes, and premature death) was characterized and the scurfy mutation was mapped to a 
gene named Forkhead box p3 (Foxp3)103. A seminal study showed that CD4+CD25+ T cells 
suppressed CD25- T cells activation resulting in tolerance to self-antigen104, and this 
subpopulation expresses Foxp3104,105. CD4+CD25+Foxp3+ cells were re-named as “regulatory T 
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cells”. Foxp3 is essential for Treg lineage106,107 and  lineage-specific master transcription 
factor108. Foxp3 is not only crucial for systemic tolerance in mice (especially in male mice) but 
also in humans. Patients with immune-dysregulation, polyendocrinopathy, enteropathy and X-
linked (IPEX) syndrome have a mutation in their FOXP3 gene, and induction of FOXP3 gene in 
human CD4 cells also exhibit a suppressor function 109,110.   
1.4.2 Regulatory T cells differentiation and nomenclatures 
        Treg cells are heterogeneous. To better define their function, there are at least two taxonomies 
proposed.  The first strategy is based on their developmental origin. One subpopulation of Treg 
cells is derived from CD4+CD8+ double positive or CD4 single positive T cells (CD4SP) in the 
thymus, is self-antigen reactive, and are called thymus-derived Treg (tTreg) cells. These were also 
called natural-occurring Treg (nTreg) cells.  Another Treg cell population is derived from CD4SP 
cells in the periphery to be a mix of non-self- and self-antigen reactive cells, called periphery-
derived Treg (pTreg) cells. Importantly, the pTreg consist of the original tTreg cells that migrated 
out of the thymus and the inducible iTreg cells that differentiated from Foxp3- naïve CD4 T cells 
(see section I.3 above about CD4 T helper cells differentiation). The old name of pTreg cells was 
adaptive Treg or inducible Treg (iTreg) cells before the nomenclature simplification111. There are 
several studies suggesting biomarkers that differentiate tTreg from pTreg, including Helios112,113 
and Neuropilin-1 (Nrp1) 114,115. But their reliability and the conclusiveness of their relative 
functional contribution to maintaining peripheral tolerance are unclear so a second classification 
evolved based on their homeostatic status. CD62LhiCD44loFoxp3+ cells are called central Treg 
(cTreg) cells and are relatively quiescent  with respect to proliferation, express high levels of Bcl-
2 and Mcl-1, reside in lymphoid organs because of the CCR7+ signature, and have high CD25 
(IL2 alpha chain receptor) expression to entrap exogenous IL-2. In contrast, 
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CD44hiCD62LloFoxp3+ effector Treg (eTreg) cells are more proliferative and are abundant in non-
lymphoid tissue (e.g. lung, gut, adipose tissue)116,117. There were some reports suggesting that 
cTreg and eTreg cells can be selectively regulated by different signals117–120, but the relation 
between Treg homeostatic status and their function status remains unclear.  
         
Figure 1.5 Treg subsets and subphenotypes5 
    tTreg cells are derived from CD4+CD8+ double positive or CD4+ single positive cells. pTreg 
cells consist of Treg cells that migrated from the thymus and inducible iTreg cells derived from 
naïve T cells. As the thymus is a primary lymphoid organ, most of the Treg cells express 
CD62LhiCD44lo and are cTreg cells. cTreg cells acquired effector status in secondary lymphoid 
organ (SLO) and non-lymphoid tissue (such as lung) after encountering antigens and stimulating 
cytokines.  
 
        Regulatory T cells can also be defined by their function. For example, IL-10-producing CD4 
T cells are called type 1 regulatory T cells (Treg1)121. We will introduce Treg function in the next 
section. 
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1.4.3 Regulatory T cells function 
        Treg cells are ‘a jack of all trades’. Over decades of study, we now know that Treg cells not 
only prevent autoimmunity as originally defined but also drive tolerance in multiple diseases and 
physiological states (e.g pathogen-induced pathology, allergy, oral tolerance, fetal tolerance…etc). 
This versatility represents the diversity of Treg cell function and as we shall see, the heterogeneity 
of its suppression mechanisms.  
Figure 1.6 Treg function6 
       Of the two classifications of suppression mechanisms one is contact-dependent and the second 
is contact-independent. In the contact-dependent suppression there are two different mechanisms.  
In the first suppression mechanism, Treg cells in SLO inhibit effector T cells indirectly through 
the modulation of DC function in vivo. After interacting with Treg cells, these DCs are unable to 
present antigens to Foxp3- conventional T (Tconv) cells 122–124. Also, Treg cells compete with 
Tconv cells for TCR/co-stimulation activation to suppress Tconv proliferation through functional 
molecule. These ‘functional molecules’ have been proposed based on the transcriptome and 
surface marker comparison between Foxp3+Treg and Foxp3- Tconv cells. These include CTLA-
4, Lag3, PD-1, ICOS, OX40. For example, CTLA-4 competes with CD28 for co-stimulation 
activation, and Lag3 competes with CD4 to form the TCR-CD3-CD4 activation complex. Not all 
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functional markers are TCR-co-stimulation dependent. Treg PD-1 receptors have their own ligands 
on DC that after receptor ligand binding renders the Tconv proliferation. One caveat is that several 
of these functional markers are not Treg cell specific. PD-1 is also expressed on exhausted CD8 T  
cells, ICOS and OX40 are also expressed on activated Tconv cells, and Lag3 is on Foxp3- IL-10 
producing T regulatory 1 cells (Treg1). Thus, since many of these functional markers are not 
exclusive to Treg cells, other functional assays are required to define Treg cells. 
        The second, contact-dependent Treg cellular suppression mechanism is through cytotoxicity. 
Similar to effector CD8 T cells, Treg cells can secrete both Granzyme B (GzmB) and perforin to 
directly kill the effector T cells42,125. This mechanism is more prevalent in non-lymphoid tissues 
since GzmB is activated after T cell activation when it is found to be abundant in eTreg but not 
cTreg cells. 
        As mentioned above, Treg cells can also suppress effector T cells in a contact-independent 
manner. Treg cells are prone to secrete anti-inflammatory cytokines including  IL-10 and TGF-b 
in non-lymphoid tissues such as gut126,127. IL-10 was originally identified as one of the Th2 
cytokines128, but numerous studies now suggest that it can be secreted by Treg and other CD4 T 
cells (ex Treg1, iTreg, Th1, Th17)121,129–131. IL-10 from Treg cells is required to impede mucosal 
inflammation in the gut132.  IL-10+Foxp3+ Treg cells only exist in the gut in steady state but not in 
other SLOs or non-lymphoid tissue because IL-10 secretion by Treg cells depends on TGF-b in 
vivo 133,134. 
        TGF-b is required for iTreg induction and differentiation (see section 1.4.4 below), and the 
idea that the secretion of TGF-b from Treg cells is part of the suppression function is plausible. 
Although TGF-b knockout Treg cells are as functional as wild type Treg cells in the in vitro 
suppression assay135, in vivo experiments show that TGF-b receptor knockout Treg cells fail to 
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suppress Tconv136. TGF-b production by Treg cells inhibits colitis and Th1 differentiation137,138. 
These recent findings suggest an extrinsic role for TGF-b secreted from Treg cells to suppress 
Tconv cells , supporting the older hypothesis that TGF-b is essential for Treg cell survival137.  
        Treg cells have high expression levels of IL2Ra (CD25) to bind IL-2, an interaction needed 
for their own survival139. Since IL-2 is also essential for Tconv cell survival, Treg cells could 
outcompete the Tconv cells for this cytokine and thus control the viable number of Tconv cells, as 
suggested in the in vitro suppression assay105. 
 
1.4.4 Foxp3 induction: outside-in signals and cis-regulatory elements 
        Foxp3 is the most indispensable factor in Treg cell fate specification, while it’s still debatable 
if Foxp3 is the ‘sole requisite’ to define Treg (See Section 1.4.2 above).  
 
Figure 1.7 Foxp3 induction is regulated by multiple signals and cis-regulatory elements 
         
        There are three consensus non-coding sequence (CNS) –CNS1, CNS2, and CNS3—that are 
well-conserved through out mammals and function as enhancers140. Foxp3+ Tregs cells are subject 
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to higher order regulation by epigenetic modifications of the conserved non-coding sequences 
(CNS) in the Foxp3 locus141–143, adding to the complexity in the canonical Foxp3-centric scheme 
of Treg differentiation 
         A body of work has identified the out-side-in regulator of Foxp3. TCR activation, TGF-b, 
and IL-2 have all been shown to contribute to Foxp3 regulation. TCR appears to be the primary 
determinant of Treg cell differentiation, and the Treg cells’ TCRs mostly recognize self-antigens 
with high-affinity 144–146. TCR activation is also required for peripheral pTreg differentiation. The 
TCR activation pathway could induce CD4 tolerance to non-self antigens (e.g. pathogenic 
pathogens as well as commensal bacteria). Activation of TCR stimulates downstream signals that 
are required for Foxp3 expression: namely nuclear factor of activated T cells (NFAT), nuclear 
factor-kB (NF-kB), and Protein kinase B (Akt)--Forkhead box O 1 (Foxo1)147–149. NFAT and 
Foxo1 directly bind to the Foxp3 promoter, and NF-kB is on conserved non-coding sequence 3 
(CNS3) (Figure 1.6).  
        TGF-b facilitates Foxp3 expression in vitro150, and TGF-b signaling is required for Foxp3+ 
Treg cell differentiation in vivo, especially pTreg cells during mucosal homeostasis and 
inflammation151–153. TGF-bRII knockout in T cells have decreased numbers of pTreg cells as well 
as multi-organ autoimmunity. TGF-b could activate the Smad2/Smad3 complex for binding to 
Foxp3 CNS1 element, which is also the Foxp3 5’ enhancer. CNS1 supports extrathymic iTreg cells 
and impedes Th2-type mucosal inflammation. Deletion of CNS1 did not lead to unprovoked multi-
organ autoimmunity or Th1 and Th17 inflammation154.  
        Although the requirement of IL-2 and IL-2Ra (CD25) in Treg cell early development and 
function was plausible139, currently the consensus is that IL-2Rb and STAT5 activation are 
required for stability and functionally developed Foxp3+ Treg cells in vivo155–157. Moreover, this 
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regulation required CNS2. CNS2 is the 3’ enhancer that is required to maintain Foxp3 stability 
and inheritance in vivo158,159. CNS2 contains CpG island for another layer of regulation—
epigenetics. We will discuss Treg epigenetics in section I.6.2.  
1.4.5 Regulatory T cells stability and plasticity 
        Treg cell stability means Treg could retain their Foxp3+ feature in different eviromental 
stimuli. Currently, Treg stability remains controversial in vivo. Bluestone and colleagues first 
provided evidence to suggest Treg cell instability by using lineage-tracing Foxp3-GFP-Cre X 
Rosa-STOP-YFP. Their evidence showed that Foxp3 Treg cells are unstable and lost their Foxp3 
expression in inflammatory microenvironment (for example Type 1 diabetes) to become GFP-
YFP+ ‘ex-Treg’ and pathogenic effector T cells160. But Rudensky and colleague later using Foxp3-
GFP-CreERT2 that was inserted in the endogenous Foxp3 locus to show that ex-Treg was not 
changed in lymphopenic conditions and Th1 infection161. This conflict was later reconciled by 
Hori and colleagues when they inserted Foxp3-GFP-Cre in the endogenous locus. They found 
GFP-YFP+ eTreg cells that produced cytokines, but these ex-Treg cells consisted of only 5% of 
the Treg cells derived from Foxp3- Tconv cells 162.  Together, these studies demonstrate that: 1) 
most of Treg cells are stable in vivo; 2) unstable Treg cells are mostly iTreg cells and demonstrate 
the adaptability of Treg in different microenvironments, while this versatility may challenge the 
concept of iTreg cells as a therapeutic agent.  
        Besides stability, the emerging paradigm of paired differentiation between Treg and effector 
T cells demonstrates that Treg cells possess plasticity in that they co-express the transcriptional 
program of specific effector T cells163. For example, Foxp3+ Treg cells acquire T-bet+ to become 
Th1-like Treg cells and then they accumulate at sites of type 1 inflammation (e.g. Mycobacterium 
tuberculosis infection)164. Also, the expression of IRF4+ in Treg cells is able to control type 2 
  21 
inflammation since Treg-specific deletion of IRF4 exhibited increased IL-4, IL-5, and IgE 
antibodies165. Interestingly, the master transcription factor of Th2—GATA3—is also expressed in 
Treg and it is required for Foxp3 expression and function166. Further, STAT3 expression in Treg 
cells skews it to a Th17-like Treg cell phenotype to prevent spontaneous intestinal Th17 
inflammation167. Also,  there are IL-17A producing and RORgt+ Treg cells in the small intestine. 
The function of RORgt+ Treg cells are still unknown. In earlier reports, in Th17-like Treg cells, 
Foxp3 antagonized RORgt function and inhibited IL-17A, suggesting that loss of Foxp3 expression 
allowed Treg cells greater Th17 plasticity with pathogenic effector function 168,169, e.g, allergic 
airway inflammation170. However, another study suggested that RORgt+Foxp3+ Th17-like Treg 
cells are suppressive in a colitis model171. Another example of plasticity is Th2-like Treg. While 
Th2-like Treg cells are pathogenic in a food allergy model172, another report suggests that it’s still 
have the suppression function in a worm infection model166. All these results are still being studied, 
and further knowledge about Treg plasticity will contribute to the more precise manipulation of 
Treg cells resulting in better therapeutics.  
   
1.5 Epigenetics and its role in regulatory T cells 
1.5.1 Epigenetic mechanisms in the development and maintenance of Treg 
        Treg cell biology is complex because Foxp3 expression per se might not be stable and 
sufficient for maintaining Treg phenotypes and functions. For example, CD4 T cells from human 
peripheral blood are FOXP3+, not suppressive and produce inflammatory cytokines173. In a murine 
model, Foxp3gfp mice that disrupt Foxp3 expression after Foxp3 promoter is activated by the GFP 
label shows that there are GFP+ but Foxp3— populations that still can express Treg functional 
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markers including CTLA-4174. Moreover, overexpression of Foxp3 in Tconv cells doesn’t 
reconstitute many Treg cell signatures and functional markers175. Together, the inconsistent 
expression of Foxp3 and Treg cell functional markers suggests that Treg cell development is not 
simple. Foxp3 expression itself may not be sufficient to define the Treg fate and function. Other 
layers of regulation are to be expected and explored.  
        Post-translational modifications that alter gene expression without changing the DNA 
sequence, are called “epigenetic modifications”. Epigenetic alterations, including histone 
modifications, DNA methylation, chromatin remodeling, and microRNAs, play indispensable 
roles in cell differentiation176,177 and many other normal and malignant cellular functions. There 
exists a heritability aspect of epigenetic modifications that is relevant here as a layer of regulation 
that may provide mechanistic answers to T cell fate phenotypes177,178.  
        DNA methylation plays a critical role in Treg cell fate phenotype. Recent genome-wide 
analyses revealed that tTreg and in-vivo derived pTreg are hypomethylated around Foxp3 CNS2, 
while Foxp3- Tconv cells and Foxp3+ iTreg cells have more CpG island methylation179,180. The 
methylation status correlates with Foxp3 stability since iTreg cells are less stable than tTreg cells 
(see section I.5.5), and demethylated CNS regions becomes accessible to transcription factors 
including Ets-1 and STAT5181. There are several DNA demethylases that are also responsible for 
Foxp3 stability and Treg cell maintenance in vivo, including TET1/2182–184.  
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Figure 1.8 Histone 3 lysine modifications in Foxp3 regulation 
Histone modifications are also critical in Treg differentiation. The histone 3 lysine 4 tri-
methylation (H3K4me3) and histone 3 lysine 27 tri-methylation correlate with gene expression or 
gene repression of Foxp3 reciprocally in Treg cells185 (Figure 1.8). The permissive epigenetic 
marks, histone 3 lysine 4 tri-methylation (H3K4me3), is mostly enriched around the Foxp3 CNS1 
segment and the Foxp3 promoter but not as significantly around CNS2 and CNS3140 . The 
suppressive mark, H3K27me3, was removed from the Foxp3 promoter and the  CNSs elements 
compared to these regions in uncommitted naïve CD4 T cells185.  
        There is H3K27 demethylases reported to be involved in Treg cell development in vivo. EZH2 
demethylase removes H3K27me3 around Foxp3-bound genes to stabilize Treg cell phenotype186 
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and enhance the suppressive function in response to inflammation187. On the other hand, MLL4 
adds the H3K4me1 mark for early tTreg survival but not for pTreg cell function188, but the role of 
an H3K4 tri-methylase in Treg differentiation is relatively unexplored. Our lab first identified that 
SMYD3, which is a protein methylase and H3K4 di- and tri-methyltransferase189, is induced by 
TGF-b and supports pTreg cell differentiation to decrease immunopathogenesis in pulmonary RSV 
infections190. These studies demonstrate that epigenetic mechanisms are vital to Treg cell 
differentiation and stability. New two-step model that both Foxp3 expression and epigenome 
signature are required for a stable Treg lineage specification is prevalent in the field.  
1.5.2 SET and MYND domain containing protein 3 (SMYD3)  
        SET and MYND domain containing protein 3 (SMYD3) is also known as lysine 
methyltransferase 3E (KMT3E). It functions as protein methyltransferase. Smyd3 has been 
reported to be histone 3 lysine 4 di- (H3K4me2) and tri- (H3K4me3) methyltransferase189. 
Recently, SMYD3 are also reported to be histone 4 (H4) K20 methylase and protein methylase to 
have broad impact on gene regulations191,192.  
       Smyd3 is over-expressed in multiple cancers and correlates with poor prognosis in cancer 
patients. 193–198. It promotes cell growth and inhibits apoptosis in cancer cells  and thus is a cancer 
potentiator 193,194,199. Smyd3 turns on multiple oncogenic pathways including RAS-, estrogen 
receptor-, and E-caderin-driven tumorogenesis to facilitate the initiation of transcription 192,199,200. 
But the role of Smyd3 in non-cancerous models is unknown. 
        Our laboratory first showed a novel role for Smyd3 in CD4 T cells. Agreeing with other 
reports, Smyd3 is TGF-b-dependent and regulates TGF-b family genes201–203. Moreover, Smyd3 
perturbed iTreg cell formation while allowing dysregulated IL-17A to worsen the 
immunopathology during RSV infection201. However,  the upstream signals that regulate Smyd3 
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and their role in maintaining tolerance to infection at mucosal surface are still unclear. The studies 
in this thesis have further elucidated that Dll4/Notch activation is a primary mediator of inducing 
Smyd3 that further stabilizes the Treg phenotype and promotes Treg function.  These changes 
include a regulatory T cell program in both Foxp3+ and Foxp3- T cells.  
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Chapter 2 Materials and Methods 
2.1 Mice 
6-8 week old female BALB/cJ and C57BL/6J mice were purchased from Jackson Laboratory. 
Female CD45.1 (B6-Ly5.1/Cr) mice were purchased from Charles River. Foxp3EGFP mice (B6.Cg-
Foxp3tm2Tch/J, stock number 006772) were bought from Jackson Laboratory and bred in house. 
Cd4-specific DNMAML mice (Cd4-Cre x R26DNMAMLf) and Cd4-specific Rbpj knockout mice 
(Cd4-Cre x Rbpjf/f) are the gift of Dr. Maillard’s lab generated as described58,204,205. Cd4-specific 
Smyd3 knockout mice was generated in our lab as described190. SMYD3tm1a (KOMP) Wtsi mice in a 
C57BL/6 background were derived from KOMP Repository at UC Davis (Davis, CA). The allele 
contains loxP and FRT sites, thus Cre and FLP deletion were used to create a SMYD3 conditional 
knockout resulting in a null allele in CD4 cells (SMYD3fl/flCD4Cre.). Cd4-specific Smyd3 knockout 
mice were backcrossed with Foxp3eGFP to create Foxp3-GFP labeled Smyd3 conditional knockout 
mice (Foxp3-GFP X SMYD3 KO). All mice were housed in the University Laboratory Animal 
Facility under animal protocols approved by the Animal Use Committee in University of Michigan. 
2.2 Respiratory syncytial virus (RSV) infection 
RSV Line 19 was a clinical isolate originally from a sick infant in University of Michigan Health 
System, which has shown in animal models to mimic human infection with increased mucus 
production, more airway hypersensitivity, and exacerbated IL-13 production25,28. BALB/c mice or 
B6 mice were anesthetized and infected intratracheally (IT) with 1*105 PFU of Line 19 RSV, as 
previously described82. 
  27 
2.3 In vivo neutralization of Dll4 
For Dll4 blockade in vivo, 2.5 mg of purified polyclonal anti-Dll4 antibody or control IgG were 
injected intraperitonialy two hours before RSV infection at day 0 as described85. The same dose of 
control or anti-Dll4 antibody were given on day 2, 4, and 6.  
2.4 Histopathology 
Left lobe of the lung was fixed with 4% formaldehyde and embedded in paraffin, and 5 µm sections 
were stained with Periodic acid-Schiff (PAS) stain to detect mucus.  
2.5 RNA isolation and quantitative PCR 
RNA were extracted with TRIzol (Invitrogen) by following the manufacturers protocol, and one 
µg of total RNA was reverse transcribed to cDNA to determine gene expression using Taqman 
gene expression primer/probe sets. Dll1, Dll4, Jag1, and Jag2 were detected by SYBR as 
described69. Delta4 primers: 5’-AGGTGCCACTTCGGTTACACAG-3’ and 5’-
CAATCACACACTCGTTCCTCTCTTC-3’ were used as described69. Muc5ac and Gob5 
expression were assessed by custom primers as described 206. Detection was performed in ABI 
7500 Real-time PCR system. Gene expression was calculated using the ΔΔCt method as 2-ΔΔCt 
when ΔΔCt= experimental Ct−input Ct)-(control Ct−input Ct) and normalized with Gapdh as input 
control.  
2.6 Murine lung cells isolation 
Mice lungs were chopped then lungs and mediastinal lymph nodes were enzymatically digested 
using 1 mg/mL Collagenase A (Roche) and 25 U/ml DNaseI (Sigma-Aldrich) in RPMI 1640 with 
10% fetal calf serum for 45 min at 37°C. Tissue were further dispersed through an 18 gauge 
needle/10 mL syringe, and filtered through 100-µm nylon mesh twice. 
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2.7 Murine intestine lamina propria lymphocyte/leukocyte (LPL) isolation 
Intestinal and colon feces were flushed out by holding the intestine with forceps and flushing with 
a syringe filled with DPBS. Residual mesenteric fat tissue and Peyer’s Patches were resected. After 
placing feces removed, longitudinally opened small intestine lamona propria (SI-LP) and colon 
lamina propria (C-LP) in ice-cold 1X DPBS without Ca or Mg,  the colon or intestine were cut 
into 0.5 cm pieces. The pieces of intestine were incubated in 20 mL of predigestion solution (1X 
DPBS (-Ca -Mg)+2mM EDTA+5% FBS) for 20 min at 37oC with rotation (200rpm) in a thermal 
incubator in a 50 ml tube. The remaining pieces were passed through a 100 µm cell strainer. The 
pieces were added together into fresh predigestion solution for 20 min at 37oC under 200rpm 
rotation in a 50 ml tube. The flow-through contains colonic content with epithelial cells and can 
be decanted or stored for the isolation of intraepithelial lymphocytes (IEL). The pieces were again 
passed through a 100 µm cell strainer the remaining EDTA was washed away with 1X DPBS. The 
tissue was collected into 50 ml tubes containing 10 mL of pre-warmed digestion solution—same 
as lung digestion (RPMI+10% FBS+1 mg/mL Collagenase A+ 40 µg/mL of DNase I). The pieces 
were digested by incubation at 37°C for 30 min under 200 rpm rotation. (Colon digestion takes 
more time than small intestine). After incubation, the cell solution was rigorously vortexed for 20 
s and passed through a 40 µm cell strainer set over a 50 mL tube. The digestion was repeated 2 
times. Ideally, all gut pieces should be digested to invisible small pieces. (Colon digestion may 
take more time than small intestine). Combine the supernatants from all digestion steps in a fresh 
50 ml tube and centrifuge for 10 min at 500 xg at 20°C Discard the supernatant. Wash the pellet 
in RPMI only medium and centrifuge the cells again at 500g for 10 min at 20°C. Enriched 
lymphocyte/leukocyte are obtained by Ficoll filtration. In brief, using a Pasteur pipette, carefully 
overlay the cell suspension on top of 3 mL of the Ficoll solution in a 15 mL tube. Centrifuge the 
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Ficoll gradient for 30 min at 500 xg at 20°C without brakes (0 deceleration). Following 
centrifugation, obtain the ring of lymphocyte/leukocyte cells (@ between 2.5~3.5 mL). Wash with 
1% FBS in DPBS buffer (FACS buffer), 500xg, 5’.  
2.8 Extracellular and Intracellular flow cytometry analysis 
Mice lungs mediastinal lymph nodes were enzymatically digested as described above. The single-
cell suspension of lung and lymph nodes were stimulated with with 100 ng/mL Phorbol-12-
myristate 13-acetate (PMA), 750 ng/mL Ionomycin, 0.5 µL/mL GolgiStop (BD), 0.5 µL/mL 
GolgiPlug (BD) for 5 hours. After excluding dead cells with LIVE/DEAD Fixable Yellow stain 
(Invitrogen), cells were pre-incubated with anti-FcgR III/II (Biolegend) for 15 minutes and labeled 
with the following antibodies from Biolegend (or otherwise specified):  
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Antigen Clone Conjugates Dilution Isotype 
CD3 145-2C11 
or 17A2 
PE  
or Pacific Blue 
1:200 Rat IgG 2b 
CD4 GK1.5 APC/Cy7 1:200 Rat IgG 2b 
CD8a 53-6.7 PerCP/Cy5.5 1:200 Rat IgG1 
CD25 PC61 Pacific Blue or PE 1:200 Rat IgG1 
CD44 IM7 FITC or PE 1:200 Rat IgG2b 
CD62L MEL-14 PE/Cy7 1:200 Rat IgG2a 
CD69 H1.2F3 PE/Cy7 1:200 Hamster IgG 
I-A/I-E 
(MHC II) 
M5/114.15.2 Pacific Blue or  
Alexa700 
1:200 Rat IgG2b 
CD11b M1/70 PE/Cy7 1:200 Rat IgG2b 
CD11c N418 APC/Cy7 1:200 Hamster IgG 
CD103 2E7 APC 1:200 Hamster IgG 
Dll4 HMD4-1 PE or APC 1:200 Hamster IgG 
ICOS C398.4A PE/Cy7 1:200 Hamster IgG 
PD-1 J43, eBioscience PE 1:200 Hamster IgG 
Neuropilin-1 Polyclonal. R&D PE 1:200  
CCR7 4B12 PE 1:200 Rat IgG2a 
Lag3 eBioC9B7W PE/Cy7 1:200 Rat IgG1 
Table 2.1 Antibodies for entracellular staining 
 
For intracellular staining, cells were fixed and permeabilized with transcription factor staining 
buffer set (eBioscience). After 3 washes, cells were labeled with antibody from eBioscience:  
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Antigen Clone Conjugates Dilution Isotype 
Foxp3 FJK-16s APC 1:50~1:75 Rat IgG2a 
IL-17A eBio17B7 PE/Cy7 1:100 (Ex vivo) 
1:200 (In vitro 
culture) 
Rat IgG2a 
IL-13 eBio13A PE 1:100 Rat IgG1 
GATA3 TWAJ PE 1:100 Rat IgG2b 
RORgt AFKJS-9 PE 1:100 Rat IgG2a 
CTLA-4 UC10-4B9 PE 1:100 Hamster IgG 
Granzyme B NGZB PE 1:100 Rat IgG2a 
H3K4me3 Polyclonal 
(Millipore) 
FITC anti-rabbit 
Ab 
10: 1:200 
20 :1:200 
 
Table 2.2 Antibodies for intracellular staining 
 
Antibodies were incubated with cells for 30 min at room temperature. After 3 times washing, flow 
cytometry data were acquired from a LSR II (BD) or a Novocyte (ACEA) flow cytometer and 
were analyzed with FlowJo software (TreeStar).  
2.9 Cell sorting and suppression assay 
Single cell sorting was performed on FACSAria II (BD).  For RNA analysis, viable CD4 and CD8 
T cells were directly sorted into TRIZoL reagent; for suppression assays, DAPI−CD4+eGFP+ 
viable Treg cells were sorted with more than 93% efficiency. Suppression assays were performed 
as described with small modification 207. In brief, naïve T cells isolated from CD45.1 mice were 
labeled with Cell Trace Violet (CTV) (Invitrogen). 2.5 X 104  of CTV-labeled CD45.1+ naïve T 
cells were co-cultured with serial-diluted EGFP+ Treg cells in a 96 well round bottom plate. 0.625 
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µL of Dynabeads® mouse T activator CD3/CD28 (Invitrogen) were added to 0.2 mL of culture. 
After 72 hours, cells were harvested, and CD45.1+ responder cell proliferation was accessed by 
CTV dilution.  
2.10 Lymph node re-stimulation and cytokine production assay 
5X105 cells from mediastinal lymph nodes were plated in 96-well plates and re-stimulated with 
105 RSV for 48 hours. IFNg IL-4, IL-5, IL-13, IL-17A, IL-10, IL-9 levels in the supernatant were 
measured using a Bio-plex cytokine assay (Bio-Rad).  
2.11 Naïve CD4 T cell isolation and stimulation 
CD4+CD25-CD62LhiCD44lo naïve T cells were enriched from wild type B6 spleen using the naïve 
CD4 T cells isolation kit (Miltenyi Biotec) to more than 92% purity. Naïve T cells were then plated 
and cultured in round-bottom 96-well plates (for luminex analysis) or 24-well plates (for CD4 T 
cells skewing). 2X105/ml to 106/ml of naïve T cells were stimulated with plate-bound anti-CD3 
(2.5 µg/ml; eBioscience), soluble anti-CD28 (3 µg/ml; eBioscience), and plate-bound recombinant 
Dll4 (1.65 µg/mL or the dose mentioned; R&D); to skew toward in vitro-induced Treg cells (iTreg), 
human TGF-b (2 ng/ml; R&D System) and mouse IL-2 (10 ng/ml; R&D System) were added at 
the same time;  to skew toward Th17 cells (Th17), mouse IL-6 (10 ng/ml; R&D System), human 
TGF-b (2 ng/ml; R&D System), anti-IFNg neutralizing antibody (10 µg/mL; eBioscience), anti-
IL-4 neutralizing antibody (10 µg/mL; eBioscience), and anti-IL-12/23 p40 neutralizing antibody 
(10 µg/mL; eBioscience) were added at the same time. 
2.12 Chromatin Immunoprecipitation (ChIP) 
ChIP was performed based on manufacturer’s instruction (Upstate Biotechnology) as described208. 
In brief, 2*106 stimulated T cells were cross-linked with 1% paraformaldehyde for 10 min in room 
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temperature. Cross-linking was stopped with 1X glycine, then cells were frozen. After lysing the 
cell pellet in 200 uL SDS lysis buffer, the resulting lysate was sonicated using a Branson Sonifier 
450 (VWR, West Chester) under the following condition: 3 times for periods of 11 seconds each. 
After centrifuging, the supernatant was diluted and 2% were saved for Input. Other diluted 
supernatant underwent immunoprecipitation at 4°C overnight with the following antibodies:  
Antigen Brand; Clone or concentration Ab/Dilution V Results 
IgG control Millipore; 1 mg/mL  2uL/500uL O 
H3K4me3  Millipore/Abcam; 1 mg/mL 2uL/500uL O/O 
H3Ac Millipore;  1 mg/mL 2uL/1000uL O 
RBP-Jk Abcam; 1 mg/mL  2.5 uL/500uL O 
N1ICD Cell signaling;D3B8 2.5 uL/500uL X 
SMAD3 Cell signaling;C67H9 5 uL/500uL X 
H3K79me3 Millipore; 0.7 ug/mL 3 uL/500uL O 
Table 2.3 Antibodies for chromatin immunoprecipitation 
 
or rabbit IgG as a control (Millipore). The precipitated complex was pulled down by protein A 
beads and cross-linking was reversed by high salt in 5 hours under 65°C. DNA was purified by 
standard phenol/chloroform and ethanol precipitation and was subjected to real-time PCR. ChIP-
specific enrichment was calculated using the ΔCt method as 2-(experimental Ct−input Ct) 
Smyd3 promoter: 5’-ACAGGGCTTCTCTGTTGTATAGC -3’ and 5’-
GAGTTTAAAGCCAGCGTGGT -3’ 
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2.13 Immunoblot analysis 
Total cells lysates were prepared using 1X Cell Lysis Buffer (Cell Signaling). The same amount 
of  total proteins (3~10 µg) were separated by Nu-PAGE(Invitrogen) and transferred onto a 
nitrocellulose membrane. The primary Ab was diluted in 5% BSA in 1X TBST and incubated 
overnight. The secondary Ab—anti-Rabbit-HRP (Cell signaling)—was diluted in 5% non-fat milk 
in 1X TBST for 1 hour. Protein bands were visualized and quantified with SuperSignal West Femto 
Masimun Sensitivity substrate.  
Antigen Brand Dilution Secondary 
SMYD3 Abcam; ab16027 and 
ab187149 
1:500 Rabbit 
Notch 1 intracellular cleaved 
domain (N1ICD) 
Cell Signaling; #4147 1:1000 Rabbit 
H3K4me3 Abcam; ab8580 1:1000 Rabbit 
H3 Cell Signaling : #9715 1: 1000 Rabbit 
Table 2.4 Antibodies for Western blotting 
 
2.14 RNA sequencing sample preparation 
Naïve CD4 T cells (CD4+CD25-CD62LhiCD44lo) were enriched as described above from three 
10~13 weeks old female Cre- control and three Cre+ Smyd3 conditional knockout mice. After 48 
hours of iTreg differentiation, total RNA was extracted using TRIzol and cleaned with QUIAGEN 
RNA CleanUp kit. The cDNA library was converted from mRNA using the following condition: 
non strand specific, poly-A selection. Deep sequencing was performed on HiSeq-4000 platform 
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with 50 bp single strand sequencing. The fragment length is around 120nt with 30 to 40 million 
reads per sample.  
2.15 RNA sequencing data analysis pipeline 
FastQC—Trimmomatic—HISAT2—Samtool—HTSeq—DESeq2 pipeline were performed for 
RNA sequencing data analysis. After download the fastq.gz file from DNA sequencing core, 
FastQC were implemented. All of our 12 samples were pass the quality control by Fast QC. Second, 
Trimmomatic-0.36 was downloaded with binary model and coded using ~bash (Terminal in 
MacOS). Quality scores were at the highest (40) in every sample. Third, the reads were aligned to 
that of the reference genome using HISAT2 under bash. The reference genome is GRCm38 in 
Ensembl. After alignment, the .sam file was compressed with Samtool to become a  .bam file.  
Fourth, we counted the reads in genes using HTSeq under Python. Raw counts and htseq.out file 
were the outputs. Finally, DESeq2 under R were implemented to normalize the reads and do 
differential analysis with Likelihood Ratio Test (LRT). Principle component analysis (PCA), Venn 
diagram, volcano plots, and heatmap were performed and drawn in R. Gene Ontology were 
performed using DAVID Bioinformatics resources 6.8, and treemap were drawn by REVIGO.  
2.16 Statistical analysis 
Data were analyzed by Prism6 (GraphPad). Data presented are mean values ± SEM. Comparison 
of two groups was performed in unpaired, two-tailed, Student’s t-test. Comparison of three or more 
groups was analyzed by ANOVA with Tukey’s post-tests. Significance was indicated at the level 
of *:p<0.05, **: p<0.005, ***: p<0.0005 
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Chapter 3 Notch Ligand Dll4 Reduces RSV Immunopathology and Sustains Treg Identities 
3.1 Abstract 
Treg cells establish tolerance, prevent inflammation at mucosal surfaces, and regulate 
immunopathology during infectious responses. Recent studies have shown that Delta-like ligand 
4 (Dll4) was up-regulated on antigen presenting cells after RSV infection and its inhibition lead to 
exaggerated immunopathology. The present studies outline the role of Dll4 in Treg cell 
differentiation, stability and function in RSV infection. Here we found that Dll4 was expressed on 
CD11b+ pulmonary DC in the lung and draining lymph nodes in wild type BALB/c mice after 
RSV infection. Dll4 neutralization exacerbated RSV-induced disease pathology, mucus 
production, group 2 innate lymphoid cells (ILC2) infiltration, IL-5 and IL-13 production, as well 
as IL-17A+ CD4 T cell infiltration. Dll4 inhibition decreased the abundance of 
CD62LhiCD44loFoxp3+ central Treg cells (cTreg) in draining lymph nodes. The RSV-induced 
disease was accompanied by an increase in Th17-like effector phenotype in Foxp3+ Treg cells and 
a decrease in Granzyme B expression after Dll4 blockade. Finally, Dll4-exposed induced iTreg 
cells maintained a CD62LhiCD44lo cTR cell phenotype, had increased Foxp3 expression, became 
more suppressive, and were resistant to Th17 skewing in vitro. These results suggest that Dll4 
activation during differentiation sustained Treg cell phenotype and function to control RSV 
infection. 
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3.2 Introduction 
Notch is a highly conserved signaling pathway that contributes to cell differentiation and function. 
Engagement of Notch receptors (Notch 1-4) and Notch ligands (Delta-like ligand 1, 3, 4, Jagged 
1, 2) initiates cleavage of the Notch intracellular domain (NICD). NICD binds to recombination 
binding protein-J (RBP-Jk) and activates the transcription of Notch target genes in association 
with a co-activator of the Mastermind like family (MAML 1-3).  Notch signaling regulates various 
stages of T cells lineage development and differentiation, including early stages of thymocyte 
development, as well as CD4 T helper (Th) differentiation69,71.  In the priming stage of Th cell 
differentiation, Notch ligand Dll4 sensitized antigen responses and augmented T cells activation 
74, while separate studies demonstrated that Dll4 and Notch could activate production of IFNg and 
the Th1 transcription factor T-bet 76,77,79. During Th2 differentiation, Jagged1 and intracellular 
Notch promoted Gata3 and Il4 expression 79–81, while Dll4 suppressed Il4, Il5, and Il13 75,82. 
Furthermore, Dll4 and Notch was reported to promote Th17 and Th9 differentiation by enhancing 
Il17a, Rorc and Il9 expression 86,209. Together, Notch can serve as an amplifier for persistent Th1, 
Th2, and Th17 cell differentiation 76, suggesting that it is not a skewing signal, but rather enhances 
co-activation. However the role of Dll4 and Notch signaling in Treg cells remains unresolved. 
Jagged2 and specific receptors, Notch1 and Notch3, promoted the Treg cell master transcription 
factor—Foxp3 expression and Treg cell survival 92–96, and RBP-Jk was reported to directly bind 
the Foxp3 promoter and regulate Foxp3 transcription 96.  In contrast, inactivating Notch signaling 
after Foxp3 is first expressed enhanced Treg cell numbers and promoted tolerance 70. Blockade of 
Notch receptors and Notch ligands expanded Foxp3+ T cell populations in vivo in experimental 
autoimmune encephalomyelitis (EAE), Graft-versus-host disease (GvHD), and Type 1 diabetes 
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(T1D) 97–100. However, the role of Notch ligands in subsets of Treg cells and in their resistance to 
inflammation during infection have not been well-defined.   
 Notch ligands can be induced on antigen presenting cells by pathogen-associated molecular 
patterns (PAMPs) 79,80. Pathogens themselves can also induce Notch ligands. Studies showed that 
RSV induced Dll4 expression on DC in vitro 82,210, and Dll4 blockade exacerbated RSV-induced 
Th2 airway pathogenesis 82. Since Treg cells are required to limit pulmonary inflammation and 
pathogenic Th2 responses during RSV infections 39,41,42, we hypothesized that the initial exposure 
of Dll4 may modulate peripherally-induced iTreg cell differentiation, homeostasis and stability to 
control the intensity of the immune response and lung pathology during RSV infection. In the 
present study, we report that Dll4 sustained CD62LhiCD44lo central Treg cells and solidified iTreg 
identity during infection. This study defined novel roles of Dll4 in iTreg cell subset regulation and 
iTreg cell stability.  
 
3.3 Results 
3.3.1 Up-regulation of Dll4 during RSV infection on CD11b+ pulmonary DC 
Previously published data have shown that Dll4 expression was up-regulated on DC post RSV 
infection in vitro 82,210. To further characterize the expression of Dll4 during RSV infection in vivo, 
BALB/cJ mice were intratracheally (i.t.) infected with 1 X 105 pfu of RSV before harvesting of 
lung tissues at 2 and 6 days post infection (dpi).  Dll4 transcripts were up-regulated significantly 
at 6 dpi, while transcripts for the other Notch ligands Dll1, Jagged (Jag) 1 and Jag2, were not 
increased in the lung (Figure 3.1).   
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Figure 3.1 Notch ligand expression kinetics during RSV infection 
Abundance of Dll1, Dll4, Jag1, and Jag2 mRNA in RSV-infected lung at the indicated time 
points relative to uninfected naïve lung. *: p<0.05 
 
        After gating on MHChi CD11c+ DC, Dll4 expression level consistently was increased on 
MHCIIhi CD11c+ DC after 6 dpi (Figure 3.2).  
 
 
Figure 3.2 Notch ligand Delta-ligand 4 (Dll4) is up-regulated on MHCIIhiCD11c+ 
pulmonary DC post RSV infection 
Lung cells from either uninfected naïve mice or RSV-infected Balb/c mice were immunostained 
with MHC-II, CD11c, and Dll4. MHCIIhiCD11c+ pulmonary DC population were gated, and 
Dll4 expression were measured. *: p<0.05 
 
        To further understand which type of DC expressed Dll4 after RSV infection, two populations 
of pulmonary DC were identified as follows to determine Dll4 expression: MHCIIhi CD11c+ 
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CD11b+ CD103− DC and MHCIIhi CD11c+ CD103+ CD11b− DC. CD11b+ DC expressed Dll4, 
whereas few of the CD103+ DC expressed Dll4 during RSV infection (Figure 3.3).  
 
Figure 3.3 Dll4 is prevalent on MHCIIhiCD11c+ CD11b+ conventional DC but not much on 
MHCIIhiCD11c+ CD103+ DC post RSV infection 
Lung cells from either uninfected naïve mice or RSV-infected Balb/c mice were immunostained 
with MHC-II, CD11c, CD11b, CD103, and Dll4. MHCIIhiCD11c+CD11b+ conventional DC and 
MHCIIhiCD11c+CD103+ DC were gated, and Dll4 expression were measured. ***: p<0.0005 
 
When we examined the number of DC in lung and draining lymph node at 6 dpi, increasing 
numbers of Dll4+ CD11b+ DC in both lung and the draining LN--mediastinal lymph node (mLN) 
were detected as the infection progressed (Figure 3.4). In contrast, the number of Dll4+ CD103+ 
DC was significantly lower and variable in lung (left) or mLN (right) after infection (Figure 3.4).  
 
Figure 3.4 Dll4+CD11b+ DC is more enriched than Dll4+CD103+ DC post RSV infection 
Lung cells from either uninfected naïve mice or RSV-infected Balb/c mice were immunostained 
with MHC-II, CD11c, CD11b, CD103, and Dll4. The numbers of MHCIIhiCD11c+CD11b+Dll4+ 
and MHCIIhiCD11c+CD103+Dll4+ were counted. *: p<0.05, **: p<0.005 
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       These data indicated that Dll4 was expressed on pulmonary DC, especially CD11b+ DC, after 
RSV infection in vivo. 
3.3.2 Inhibition of Dll4 exacerbated RSV-induced immunopathology in vivo 
        Next, we explored the role of Dll4 in controlling RSV immunopathology by blocking Dll4 in 
vivo during RSV infection. We have previously demonstrated that our polyclonal anti-Dll4 
antibody is specific for Dll4 and not other Notch ligands82. The polyclonal anti-Dll4 antibody 
decreased the abundance of Notch target gene Hes1 transcripts in activated T cells (Th0) in co-
culture with fixed Dll4-expressing stromal cells (Figure 3.5), indicating that anti-Dll4 antibody 
blocked Dll4-mediated Notch activation in vitro. We next aimed at blocking Dll4 in vivo by 
injecting 2.5 mg of purified anti-Dll4 antibody intraperitoneally (i.p). Mice were then infected i.t 
with RSV 2 hours after antibody injection at day 0, followed by i.p injection of anti-Dll4 every 
other day. After 8 days, the abundance of Hey1—Notch target gene transcripts was decreased in 
the lung and sorted CD4 T cells from mLN (Figure 3.5) of anti-Dll4-treated mice, suggesting that 
systemic administration of anti-Dll4 antibodies inhibited Notch signaling activation in CD4 T cells 
in vivo.  
 
Figure 3.5 Anti-Dll4 neutralization impedes Notch signaling activation demonstrated by 
Notch target gene expression in vitro and in vivo 
A. OP9 cells (OP9-control) and Dll4-transduced OP-9 cells (OP9-DL4) were cultured in the 
105/ 24 wells and fixed with 4% formaldehyde to provide Notch ligand Dll4 without 
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mRNA production. After pre-incubating 2 µg of anti-Dll4 antibody or control IgG for 15 
minutes, 106 of naïve CD4 T cells were culture on OP9-control or OP9-DL4 for 2 hours. 
CD4 T cells were harvested, and Hes1 expression was measured.  
B. Notch target genes Hey1 in the lung were measured at 8 dpi to examine the efficacy of Dll4 
neutralization.  
C. Viable CD4 T cells in mediastinal lymph node from individual mice were sorted, and Notch 
target gene Hey1 were measured to examine the efficacy of Dll4 inhibition in CD4 T cells. 
N=5 in each group.  
Data represent mean ± s.e.m. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance 
(unpaired two-tailed t-test)  
      
        Dll4 blockade increased peribronchial infiltration by mononuclear cell clusters and drove 
mucus production in the airway as assessed in periodic-acid Schiff (PAS)-stained lung sections 
(Figure 3.6A). As an indication of RSV-induced pathology, expression of the mucus-associated 
gene gob5 (mClca3) was substantially increased (Figure 3.6B), but the viral titer measured with 
RSV-F and RSV-G didn’t have any significant difference at both 6 dpi and 8 dpi (Figure 3.6C 
and data not shown). Thus, Dll4 targeting significantly altered lung immunopathology during RSV 
infection. 
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Figure 3.6 Blockade of Dll4 drives mucus production in lung but not affect the abundance 
of RSV viral gene at 8 dpi of RSV infection 
A. Periodic acid-Schiff (PAS) staining of formalin-fixed lung section from 8 dpi. Bar, 200 µm. 
indicates the detection of mucin, and  designates mononuclear cells aggregates.   
B. Gob5 expression in the lung at 8 dpi.   
C. RSV-F viral fusion protein gene expression in lung at 8 dpi. ND: non-detectable 
 
        Besides CD4 T cells, RSV infection also activated ILC2 cells between 4 to 6 dpi in lung to 
be mucogenic and immunopathogenic 8. Here we investigate if Notch ligand Dll4 affects ILC2 
homeostasis. The gating strategy is shown in Figure 3.7.  Strikingly, Dll4 inhibition increased the 
number of Lin—CD45+CD127+ST2+CD25+ ILC2 cells in lung (Figure 3.7) and and mLN (data not 
shown) at 6 dpi. Thus, Dll4 targeting significantly altered lung immunopathology during RSV 
infection. These data suggested that Dll4 blockade enriched ILC2 in airway during RSV infection.  
 
Figure 3.7 Blockade of Dll4 increased the number type 2 innate lymphoid cells (ILC2) at 6 
dpi of RSV infection 
Balb/c mice were infected with RSV, and Dll4 were inhibited by injecting 2.5 mg of purified 
anti-Dll4 antibody intraperitoneally (i.p). Lung cells in uninfected mice, cIg-injected RSV-
infected mice, and Dll4 neutralized RSV-infected mice were immunostained. Lineage- 
ILC2	gating
Lineage 
Lineage marker: CD3, CD11b, 
B220, Gr-1, TER119 
CD127
CD
45
ST2
CD
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CD45+CD127+CD25+ST2+ Type 2 Innate lymphoid cells (ILC2) were gated and counted. ***: 
p<0.0005 
 
        Excessive cytokine production is one of the key feature leading to RSV pathogenesis. IFNg 
promotes viral clearance while IL-4, IL-5, IL-13 and IL-17A are pathogenic 211–213. Here we 
determined the effect of Dll4 blockade on cytokine profiles in draining lymph nodes. The same 
number of mLN cells were cultured and re-stimulated with 105 pfu RSV. In vivo Dll4 blockade 
during RSV infection led to significantly increased Th2 cytokines IL-5, IL-13 and IL-17A while 
IFNg, IL-4, IL-9, and IL-10 were not significantly affected in RSV re-challenged lymph node 
cells. (Figure 3.8)    
 
Figure 3.8 Blockade of Dll4 drives accumulation of IL-13 and IL-17A production  
A. Mediastinal lymph node cells from control or Dll4 neutralized mice were counted, and 
5*105 of mediastinal lymph node cells were restimulated 105 pfu of RSV. After 48 hours, 
cytokines in the supernatant were measured.  
B. Mediastinal lymph node cells from control or Dll4 neutralized mice were restimulated 
with PMA+Ionomycin+Golgi Stop+Golgi plug for 5 hours. Intracellular IL-13 and IL-
17A in CD4 were stained. 
 
        To specify if Dll4 regulated T helper cell cytokine production in CD4 T cells, mLN cells were 
re-stimulated with PMA+Ionomycin and CD4 T cells were examined by flow cytometry. Dll4 
blockade significantly increased IL-13+ and IL-17A+ CD4 helper T cells in mLN in both 6 dpi 
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and 8 dpi (data not shown). These data indicated that Dll4 neutralization exacerbated RSV-induced 
immunopathology, as shown by elevated mucus production, activated CD4 T cells, and Th2-Th17 
cytokine over-production. 
3.3.3 Dll4 neutralization reduces central Treg and increases Th17-like Treg during RSV 
infection 
        Several studies demonstrated that Treg cells quickly accumulate in lymphoid tissues and in 
the airway to dampen activated T cell infiltration and Th2 responses 39–41, and that RSV infection 
drove Treg cells to Th2-like effector cells with impaired function 214. Our group showed that Dll4 
inhibition exacerbated type 2 cytokine production and activated T cell infiltration, but little is 
known about the role of Dll4 in Treg cell development, stability and function. After targeting Dll4 
as previously described, total Treg cells did not change in mLN at 6 dpi. However, when gating 
on CD62LhiCD44lo central CD4 T cells (cT), Dll4 neutralization decreased the cTreg population, 
while eTreg were not altered in mLN (Figure 3.9A~C).  CCR7-mediated signals recruit 
CD62LhiCD44lo T cells to the T cell zone, and CCR7 is a marker of cTreg cells 215. Here we also 
found that Dll4 inhibition decreased expression of the CCR7 chemokine receptor on cTreg cells 
(Figure 3.9D, E). These data suggested that Dll4 specifically sustained cTreg cells and their 
expression in mLN during RSV infection. (Figure 3.9) 
 
A B C D E
  46 
Figure 3.9 Dll4 inhibition impairs the maintenance of central Treg cells in lymph node in 
vivo 
A. Percentage of Foxp3+ cells in CD62LhiCD44lo central CD4 T cells harvested from the mLN 
at 6 dpi 
B. Percentage of CD62LhiCD44loFoxp3+ central Treg cells in mLN at 6 dpi 
C. Percentage of CD44hiCD62LloFoxp3+ effector Treg cells in mLN at 6 dpi 
D. Representative flow cytometric analysis showing CCR7 expression in CD62LhiCD44lo 
central CD4 T cells in mLN at 6 dpi 
E. E. Mean fluorescence intensity of CCR7 in CD62LhiCD44lo central CD4 T cells in mLN at 
6 dpi 
 
        We next examined if Dll4 can also perturb cytokine production in Foxp3+ CD4 T cells. Lung 
cells harvested at 8 dpi were re-stimulated and stained for intracellular Foxp3, IL-13 and IL-17A 
before flow cytometric analysis. In vivo Dll4 blockade significantly increased the abundance of 
IL-17A+Foxp3+ after PMA+Ionomycin (P+I) re-stimulation.  To further characterize if Dll4 
regulates either Th17 or Th2 transcription factor co-expression in Treg cells, RORgt or GATA3 
were co-stained with Foxp3 after re-stimulation. Dll4 neutralization increased the percentage of 
RORgt+Foxp3lo cells but not RORgt−Foxp3+ after 8 dpi (Figure 3.10) 
 
Figure 3.10 Dll4 inhibition enriches Th17-like Treg in vivo 
A. Gating strategy and percentage of IL-17A+Foxp3+ cells in viable CD4 T cells at 8 dpi. Lung 
cells were re-stimulated with PMA+ Ionomycin+ Golgi Stop+ Golgi plug 5 hours for 
intracellular cytokine staining 
B. Gating strategy and percentage of RORgt+Foxp3lo cells in viable CD4 T cells at 8 dpi. No 
stimulation is applied.  
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These data suggested that Dll4 inhibition drove a Th17-like effector phenotype in Treg cells during 
RSV infection in vivo. Surprisingly, we didn’t detect significant changes in GATA3+ Treg cells 
and even total GATA3+ CD4 T cells in both lung and LN after Dll4 inhibition (data not shown).  
          To further specify the role of Dll4 in cytokines, especially in Foxp3— Tconv cells versus 
Foxp3+ Treg cells, here we switch the mouse strain from Balb/cJ to Foxp3EGFP knock-in mice 
which have EGFP cassette knocked in downstream of an endogenous STOP codon with no defect 
in Foxp3 expression and Treg function. Foxp3EGFP knock-in mice were i.t infected with RSV and 
treated with neutralizing anti-Dll4 antibody. At 6 dpi, viable CD4+Foxp3EGFP-/+ cells from mLN 
were sorted (Figure 3.11A). DLL4 neutralization decreased Foxp3 expression in EGFP+ CD4 T 
cells (Figure 3.11C). At both 6 dpi and 8 dpi, Il17a mRNA was increased in EGFP+ but not EGFP- 
CD4 T cells (Figure 3.11B), whereas DLL4 inhibition increased Il5 and Il13 expression in EGFP- 
but not in EGFP+ mice. DLL4 inhibition differentially affected Ifng expression in EGFP- versus 
EGFP+ mice(Figure 3.11D-E).  
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Figure 3.11 Dll4 inhibition enriches more Il17a and decreases Foxp3 expression in Foxp3-
GFP+ Treg during RSV infection in vivo 
A. FACS gating strategy for CD4+Foxp3-GFP+ or CD4+Foxp3-GFP- population in mLN at 
6 dpi of RSV infection 
B. Il17a expression in Foxp3-GFP+ and EGFP- population at 6 dpi 
C. Foxp3 expression in Foxp3-GFP+ and EGFP- population at 6 dpi 
D. Ifng expression in Foxp3-GFP+ and EGFP- population at 6 dpi 
E. Il13 expression in Foxp3-GFP+ and EGFP- population at 6 dpi 
 
 To further investigate if Dll4 regulated Treg cell functional markers, several parameters 
were examined: Inducible T cells co-stimulator (ICOS), Programmed cell death protein 1 (PD-1), 
Granzyme B (GzmB), and Neuropilin-1 (Nrp1). It was previously shown that during RSV infection, 
GzmB was the critical functional molecule for Treg cell function to limit the associated 
immunopathology 42. After further gating on central vs effector Treg, we found that Dll4 
neutralization decreased the frequency of GzmB+ in Foxp3+ Treg cells in the lung after 8 dpi, 
especially prominently for GzmB+ eTreg cells (Figure 3.12). On the other hand, ICOS, PD-1 and 
Nrp1 expression were unchanged in Foxp3+ Treg cells. 
 
Figure 3.12 Dll4 harnesses cytolytic effector function in Treg, especially in effector Treg 
during RSV infection in vivo 
A. Granzyme B (GzmB) staining in Foxp3-CD4+CD3+ or Foxp3+CD4+CD3+ (Treg) cells in 
lung at 8dpi. 
B. Percent of GzmB+ in CD62LhiCD44lo central Treg (cTR), CD44hiCD62Llo effector Treg 
(eTR), and other two populations.  
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        Our results indicate that Dll4 prevented Foxp3 Treg cell acquisition of Th17-like effector 
phenotype, and it supported GzmB expression in Treg cells in the lung during RSV infection.  
3.3.4 Dll4-knockdown of DC exacerbates RSV immunopathology and Treg cell identity 
Figure 3.2~3.3 demonstrated that CD11c+ DC express Dll4 during RSV infection, and Figure 
3.6~3.8 showed that Dll4 inhibits RSV immunopathology and sustains Treg cell identity in vivo. 
To further specify if Dll4 on CD11c+ DC is directly responsible for the RSV immunopathology 
and Treg cell identity, we first tried to breed CD11c-Cre with Dll4f/f mice but obtained no Cre+ 
offspring. We then switched to UBC-Cre-ERT2 X Dll4f/f to have Cre-ERT2 expressed in all tissue 
types. ERT2 doesn’t bind to the natural ligand of estrogen receptor—17b-estradiol—but binds to 
synthetic ligand 4-hydroxytamosifen (4-OHT). After 6 days of bone-marrow derived dendritic 
cells (BMDC) culture, we treated the Cre- control or Cre+ BMDC with 1 µM of 4-OHT. 48 hours 
later, BMDCs were infected with RSV line 19 with MOI=1 for 24 hours. BMDC were subject to 
flow cytometry to confirm the knockdown with ~50% efficiency (Figure 3.13A).  At day 0, we  
i.t. transferred 2.5*105 Cre- control or Cre+ BMDC into Foxp3EGFP recipients. After 12 days post 
DC transfer i.t, male or female Foxp3EGFP recipients were re-infected with RSV, and mice were 
harvest at day 20 (8 dpi) (Figure 3.13B). We observed more Muc5ac and Gob5 mucin gene 
expression in Dll4 knockdown (KD) DC mice, although the p-value was not significant (Figure 
3.13C and data not shown). PAS positive staining mucin was visualized in lung histology as 
indicated by arrows (Figure 3.13D). To further investigate the role of Dll4 on DC in Treg cell 
identities, we stained Foxp3, CTLA-4, OX40, Granzyme B, Lag3 in CD4 T cells in lung. Treg cell 
markers were not changed by Dll4 KD DC (data not shown). To investigate if deletion of Dll4 in 
DC could affect Th17 like Treg like cells, we double stained IL-17A and Foxp3 in CD4 T cells. 
Strikingly, Foxp3 intensity in Treg cells was significantly decreased (Figure 3.13F), while there 
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was no change in IL-17A+ Foxp3- Th17 cells and very few IL-17A+Foxp3+ cells were detected 
(Figure 3.13E). Moreover, mucogenic and pathogenic IL-5 and IL-13 were increased by Dll4 
knockdown in DC (Figure 3.13G). Note that these CD4 T cells were all from wild type B6 mice. 
These data strongly emphasize the role of Dll4 in DC that promotes Foxp3 expression in CD4 T 
cells and impedes pathogenic type 2 cytokine over-production.  
 
Figure 3.13 Dll4 on DC sustains Treg identity and attenuates RSV Th2 pathology in vivo  
A. After 6 days of BMDC culture, BMDC were incubated with 1mM 4-OHT for 48 hours, 
and DC were washed before infection with Line 19 RSV for 24 hours. Dll4 expression on 
CD11c+ BMDC were examined with flow cytometry.  
B. Experimental regimen of Dll4 DC transfer experiment. 2.5*105 Wt DC or Dll4 KD DC 
were i.t transferred into wt Foxp3EGFP mice. After 12 days, both DC-transferred Foxp3eGFP 
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mice were re-infected with RSV. After another 8 days (at d20), mice were harvested for 
analysis.  
C. Expression of Muc5ac in lung from wt DC or Dll4 KD DC transferred B6 mice were 
measured at d20.  
D. PAS-stained lung section from wt DC or Dll4 KD DC transferred B6 mice to indicate 
mucin-positive signal in purple (arrows). 
E. Viable CD4+ T cells from lung were re-stimulated with P+ I for 5 hours. And IL-17A+ 
Foxp3+ cells were stained.  
F. Foxp3 mean fluorescence intensity was quantified in the Foxp3+IL-17A- CD4 T cells 
population. 
G. 2*105 mLN cells from either wt DC or Dll4 KD DC transferred B6 mice were re-stimulated 
with RSV for 48 hours. Cytokines were measured and profiled by Bioplex.  
 
 
3.3.5 Dll4 activates and maintaines inducible Treg cells in vitro 
Our data reveal differential effects of Dll4 in Foxp3+ Treg cells in lymphoid vs. non-lymphoid 
tissue during pulmonary infection. To further investigate Dll4 effects on Treg cell differentiation 
in a controlled context, splenic CD4+CD25−CD62LhiCD44lo naïve CD4 T cells were activated with 
anti-CD3/anti-CD28 with or without plate-bound recombinant Dll4, and skewed toward Treg cells 
with TGF-b and IL-2. We first confirmed that Dll4 was able to activate expression of the Notch 
target gene Hes1 in naïve CD4 T cells, Th0 and Treg cells in a dose-dependent manner and 
activated intracellular domain of Notch1 (N1ICD) cleavage (Figure 3.20).  
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Figure 3.14 Plate-bound recombinant Dll4 activates Notch signaling in both naïve CD4 T 
cells and Treg differentiation in vitro 
A. Naïve CD4 T cells were cultured in 96 well round bottom plate only or in a Dll4 coated 
plate for 24 hours. Notch target gene Hes1 was measured. 
B. Naïve CD4 T cells were cultured in either a-CD3/a-CD28 Th0 conditions +/- plate-bound 
Dll4 for 24 hours.  Notch target gene Hes1 was measured. 
C. Naïve CD4 T cells were cultured in a-CD3/a-CD28/TGF-b/IL-2 iTreg conditions plus 
plate-bound Dll4 with the indicated concentrations for 24 hours.  Notch target gene Hes1 
was measured. 
D. Naïve CD4 T cells were cultured in Th0 or iTreg conditions with or without Dll4 for 48 
hours. Cleaved Notch 1 intracellular domain (N1ICD) was detected to indicate Notch 
signaling activation. 
         
        Subsequently, naïve T cells were skewed toward Th0 or iTreg cell phenotype. Importantly, 
Dll4 increased CD25+Foxp3+ iTreg cells in a dose-dependent manner only in the presence of TGF-
b. Furthermore, Foxp3 expression was significantly decreased with homozygous ROSA26-driven 
expression of the pan-Notch-inhibitor dominant negative Mastermind-like 1 (DNMAML1), and 
with inactivation of the Rbpj gene, encoding RBP-Jk (Figure 3.21). Since MAML1 and RBP-Jk 
mediate transcriptional activation through Notch signaling, these data revealed that Dll4-activated 
Foxp3 expression was dependent upon canonical RBP-Jk/MAML-dependent Notch signaling. 
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Figure 3.15 Dll4 up-regulates Foxp3+ iTreg differentiation in TGF-b dependent and 
canonical Notch dependent manner in vitro 
A. CD25+Foxp3+ iTreg were skewed from naïve CD4 T cells for 72 hours with or without 2 
ng/mL of TGF-b and indicated concentration of Dll4 (µg/mL) 
B. Foxp3 expression after 48 hours skewing from either wild type naïve CD4 T cells or naive 
T cells expressing dominant negative MAML1 (DNMAML)  
C. Foxp3 expression after 48 hours skewing from either wild type or CD4-specific Rbpj-
deficient naïve CD4 T cells 
        
        To further characterize Foxp3+ cells in this differentiation system, primary Dll4-activated 
iTreg cultures were rested in IL-2 for 3 days without Dll4. Dll4-treated iTreg cells consistently 
maintained a higher percent of Foxp3+ cells and higher Foxp3 expression (Figure 3.16).  
 
Figure 3.16 Dll4 exposure sustains the percent of Foxp3+ and Foxp3 expression in iTreg in 
vitro 
A. Naïve CD4 T cells from wild type B6 mice were skewed toward iTreg with or without Dll4 
stimulation for 72 hours (d3), then rested in 10 ng/mL of IL-2 for another 72 hours. 
Representative flow cytometry showed the expression of Foxp3 in viable CD4 T cells at 
day 6 (d6).  
B. Percentage of Foxp3+ in viable CD4 T cells at day 6.  
A B C
A B C
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C. Mean fluorescence intensity of Foxp3 in viable Foxp3+ CD4 T cells at day 6 
 
To investigate whether Dll4 affected any homeostatic features on Treg cells during in vitro 
skewing, CD62L and CD44 expression was evaluated before or after sequential dosing of IL-2 
during rest. Naïve CD4 T cells that were exposed to Dll4 during primary iTreg cell skewing 
maintained more CD62LhiCD44loFoxp3+ cells independent of the dose of IL-2 during the rest 
period and at multiple time points after primary skewing (Figure 3.17).  
 
Figure 3.17 Dll4 exposure sustains the percent of central Treg Foxp3+ in vitro 
A. Percentage of CD62LhiCD44loFoxp3+ central Treg  (cTR) after 0 ng/mL, 2 ng/mL and 10 
ng/mL of IL-2 resting at day 6 iTreg culture 
B. Percentage of cTR at day 3 and day 6 with 2 ng/mL of IL-2 in iTreg culture 
 
        These data suggest that the presence of Dll4 during iTreg activation and differentiation 
stabilized Foxp3 expression and sustained more Treg with a CD62LhiCD44lo phenotype in vitro.  
3.3.6 Dll4-exposed iTreg cells are more suppressive and functional in vitro  
To further evaluate the function of iTreg cells after Dll4 exposure, we sorted viable, Foxp3-eGFP+ 
iTreg cells from culture on day 6 and co-cultured these cells with CD45.1+ naïve CD4 T cells as 
responders. CD45.1+ naïve T cells were labeled with CellTrace Violet (CTV) and stimulated with 
a-CD3/a-CD28 mouse T cell activator for 72 hours. Viable CD45.1+ cells were gated to examine 
CTV dilution as a readout of cell proliferation. Responder cells that were co-cultured with Dll4-
treated iTreg cells were less proliferative, especially at the 1:1 and 1:2 cell ratio of Treg: naïve T, 
A B cTreg cTreg 
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suggesting that Dll4-treated iTreg cells were more suppressive than iTreg cells without Dll4. 
(Figure 3.18). There data indicated that Dll4-exposed iTreg cells were more functional in vitro. 
 
Figure 3.18 Dll4-exposed iTreg cells are more suppressive in vitro 
Schematic representation of the in vitro suppression assay. Naïve CD4 T cells from Foxp3-EGFP 
knock-in mice underwent iTreg differentiation with or without Dll4 for 72 hours, and resting in 2 
ng/mL IL-2 for 72 hours. Viable iTreg or Dll4-exposed iTreg were sorted out as Foxp3-eGFP+ 
DAPI−, and co-cultured with CellTrace violet (CTV) labeled CD45.1+ naïve T cells with anti-
CD3/anti-CD28 beads. After 3 days in co-culture, proliferation was assessed by CTV dilution in 
CD45.1+ responder cells.  
 
3.3.7 Dll4 and Notch activation strengthen iTreg to be less plastic toward Th17 
To examine whether Dll4 and Notch signaling could inhibit acquisition of a Th17 effector 
phenotype in iTreg cells, naïve CD4 T cells were purified and cultured in iTreg skewing conditions 
and Il17a expression was examined. Inactivation of Notch increased Il17a expression during iTreg 
skewing, while Foxp3 transcripts were decreased. Both DNMAML1 expression and Rbpj 
inactivation in CD4 T cells led to increased IL-17A in iTreg Dll4 skewed cultures (Figure 3.19). 
These data suggest that intrinsic Notch activation inhibited Il17a expression while enhancing 
Foxp3 expression in iTreg cells during differentiation.  
  56 
 
Figure 3.19 Dll4 stimulation and intracellular Notch promotes Foxp3 and impedes IL-17A 
production during iTreg differentiation in vitro 
A. Splenic naïve CD4 T cells from DNMAML or wt B6 mice were skewed toward iTreg 
cells for 48 hours. Il17a expression in iTreg cell culture was measured. 
B. Foxp3 expression in iTreg cell culture was measured by realtime PCR after 48 hours of 
skewing. 
C. IL-17A secretion from iTreg cells was measured using the luminax system after 48 hours 
of skewing.  
 
To further investigate whether Dll4 affects IL-17A production after Treg cell differentiation, the 
same number of differentiated iTreg were challenged under IL-6 + TGFb Th17 skewing conditions 
for 3 more days after the standard 6 day iTreg cell skewing culture. In Th17 re-stimulation, Dll4-
treated iTreg cells secreted significantly less IL-17A with associated decreased RORgt+ cells. 
Furthermore, Dll4-exposed iTreg cells retained a higher percentage and expression level of Foxp3 
(Figure 3.20).  
  
Figure 3.20 Dll4 exposure retains Foxp3 expression and impedes IL-17A production in 
Th17 re-stimulation in vitro 
A. Naïve CD4 T cells from wt B6 mice were skewed toward iTreg with or without Dll4 
stimulation for 72 hours, then rested in 10 ng/mL of IL-2 for another 72 hours. At day 6, 
A B C 
  57 
5 X 105 of viable cells were re-stimulated in Th17 conditions. After 3 days, IL-17A in the 
supernatant was accessed.  
B. Percentage of RORgt+ in viable CD4 T cells after Th17 skewing. 
C. Percentage of Foxp3+ in viable iTreg  or Dll4-exposed iTreg after Th17 skewing. 
 
These data suggest that Dll4-mediated signals during iTreg cell differentiation led to less 
inflammatory Th17 skewing while maintaining iTreg cell commitment.  
        
To clarify if Dll4-educated Foxp3+ iTreg cells possessed less plasticity to become RORgt+ cells, 
105 viable Foxp3-eGFP+ iTreg cells were sorted after 6 days of iTreg skewing and cultured in Th17 
conditions. Approximately 40% of eGFP+ iTreg cells cultured without Dll4 acquired RORgt+ 
expression, whereas Dll4-skewed eGFP+ iTreg cells expressed significantly less and 
RORgt+Foxp3+ cells (Figure 3.21). Dll4-treated iTreg cells still retained more percent of 
Foxp3+RORgt− during Th17 skewing (Figure 3.21).  
 
Figure 3.21 Dll4 exposure solidifies iTreg phenotype to be less plastic toward Th17 in vitro 
Naïve CD4 T cells from wild type B6 mice were skewed toward iTreg cells with or without Dll4 
stimulation for 72 hours, then rested in 10 ng/mL of IL-2 for another 72 hours. 5 X 105 of viable 
Foxp3-eGFP+ cells were sorted out and re-stimulated in Th17 skewing conditions at day 6. After 
3 days 
A. The percentage of RORgt+Foxp3+ was determined.  
B. The percentage of RORgt-Foxp3+ was determined. 
 
These data suggest that Dll4-educated iTreg cells are less able to skew  toward an inflammatory 
Th17 phenotype.  
 
 
A B 
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3.4 Discussion 
 
The objective of this study was to determine if the Notch ligand Dll4 influenced Foxp3+ Treg cell 
development, homeostasis, and function during pulmonary infection. Notch signaling has been 
suggested to be instrumental in Foxp3+ Treg cell formation and maintenance 70,216. Notch 
ligands—Dll1, Jagged1 and Jagged2—have been shown to regulate Treg cell expansion and to 
elicit suppressive activity 93,96,217. The present study suggests that Dll4 mechanistically regulates 
the stability of iTreg cells. Previous studies showed that primary RSV infection enhanced Foxp3+ 
Treg cells in the airway 39,40. Our data indicate that Dll4 sustained Foxp3 expression especially in 
central Treg cells, and altered homeostatic features and functional markers of Treg cells. In vivo 
Dll4 inhibition allowed the acquisition of effector cytokine production in Treg cells, increased 
their effector phenotype (CD44hiCD62Llo), and decreased functional Treg cell markers (GzmB) 
during infection. In vitro skewing of iTreg cells co-stimulated with Dll4 from naïve T cells had 
enhanced regulatory function, retained their central Treg cell phenotype, and were more stable with 
less susceptibility to become RORgt+ Th17 cells. Importantly, stable and functional Treg cells 
prevent autoimmunity and enhance immunity against chronic infection 218. Thus, identifying Dll4 
as one stabilizing factor in autologous Treg cells could potentially further optimize clinical efficacy 
of treatment protocols 219,220.  
 Dll4/Notch signaling appears to have differential functions in various disease models. 
Using systemic blockade, Dll4 inhibition lessened GvHD, Type 1 diabetes, and experimental 
autoimmune encephalomyelitis 89,98,100,221,222. In contrast, Dll4 blockade leads to exacerbated 
allergic airway disease and pulmonary RSV infection responses, as well as to increased BCG-
induced granuloma formation 82,83. These different results could be reconciled with a revised model 
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that Notch signaling fine-tunes T cell responses to different environmental cues 76, and thereby 
plays a distinct role in different diseases, such as antigen driven/infectious vs. autoimmune or 
allogeneic responses. Recently, a study demonstrated that intrinsic Notch signaling limited 
peripheral Treg cell maintenance during steady state and in GvHD 70. In contrast to their finding, 
our results suggests that Dll4 and canonical Notch signaling sustained iTreg cell differentiation 
and stability to prevent immunopathogenesis of pulmonary infection. Recent evidence supports 
that iTreg cells are important for mucosal homeostasis, suppression of immune responses to 
environmental and food antigens, and to impede mucosal inflammation. In contrast, nTreg cells 
prevent autoimmunity and alter the threshold of immune activation 154,223. Notch signaling and 
Dll4 restrain nTreg cell development in vivo 98, and GvHD was mainly prevented by nTreg 224,225 
but not iTreg due to lineage instability of the latter 226. To answer the question if Dll4 differentially 
affect nTreg versus iTreg cells, we used Neuropilin-1 (Nrp1) to distinguish nTreg versus iTreg 
cells in vivo as described 113–115,227. Our preliminary findings showed that Dll4 inhibition decreased 
Nrp1− Treg cells during RSV infection but increased Nrp1+ Treg cells in spleen (data not shown). 
Therefore, we speculate that Dll4/Notch may have a differential role on nTreg versus iTreg cells, 
thereby limiting Treg cells in GvHD but enhancing them in RSV infection. Additional research 
needs to be done to elucidate this intriguing hypothesis.   
          Pathogenic RSV infection also exhibits a type 2-biased immune response 228. Our group has 
shown that Dll4 prevent Th2 cytokine secretion in CD4 T cells during RSV infection. Since both 
Notch signaling and Treg cells have been reported to be involved in the Th2 program, it raised the 
question: Does Dll4 regulates Th2 cytokine production directly or indirectly through Treg cells. 
Our data presented a dysfunctional Treg and Th17-like effector phenotype but not Th2-like after 
Dll4 inhibition. Since IL-17A aggravated Th2 responses in RSV infection and other pulmonary 
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inflammation, these results suggest that Dll4 mostly exacerbated Th2 cytokine production 
indirectly. Beside Th2 cells, recent studies demonstrated that RSV infection activated ILC2 cells  
with a concurrent IL-13 increase 8. The present study indicated that Dll4 inhibition drove the 
number of ILC2 cells and corresponded with elevated IL-5 and IL-13 levels. Dll1/Notch has been 
shown to support ILC2 progenitor cell development in vitro 216,229, but the in vivo role of Dll4 in 
ILC2 biology during infection has not been described. Our novel finding further highlights the 
importance of Dll4 in ILC2 homeostasis in vivo, but it is not clear whether the regulation is direct 
or indirect. Since iTreg cells inhibit ILC2 cells and attenuate pulmonary inflammation 230, future 
studies will be necessary to specify the indirect contribution of iTreg cells in restraining ILC2 cells 
during pulmonary infection.  
          The homeostatic features of Foxp3+ Treg cells were characterized with CD62L, CD44, and 
CCR7. CD62LhiCD44loCCR7+ cTreg cells are quiescent, long-lived, and dependent on IL-2, 
whereas CD44hiCD62LloFoxp3+ eTreg cells appear to be shorter lived 116,215. These two 
subpopulations favored distinct compartments, as cTreg cells homing to SLO to be suppressive for 
autoimmunity 231. Lymph node sensitization is critical to mount a proper immune response since 
insufficient lymph node formation led to impaired Foxp3 Treg cell function, promoted IL-17A-
mediated pulmonary pathology, and initiated lymphoid cell clusters in the lung 31,232. In the present 
study, the data showed that Dll4 sustained the cTreg cell population in SLO while preventing Th17 
effector phenotype during RSV infection, representing a novel role for Dll4 in cTreg cell 
maintenance.  
      In addition to the alteration of the Treg cell cytokine phenotype, the present study further 
suggests that Dll4 sustained Treg cell function by influencing GzmB in vivo and CD25 in vitro. 
Intriguingly, GzmB in Foxp3+ Treg cells controlled RSV-induced T cell infiltration in airways 42, 
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and GzmB has been postulated to be a better functional marker of iTreg cells during viral infection 
233. Further investigation on the function of Treg subsets during RSV infection needs to be 
undertaken. Here, our findings with GzmB may provide a mechanistic explanation for how Dll4 
inhibition exacerbates RSV-induced CD4 and CD8 T cells infiltration82.  
           Taken together, our study demonstrates that Dll4/Notch promotes iTreg cell development, 
homeostasis, stability/plasticity, and functions in vitro and in vivo during RSV infection. Dll4 
prevented RSV pathogenesis and supported iTreg cell development in vitro.  The effects of Dll4 
on Treg cells are an example of how Notch signaling can promote T cell homeostasis and disease 
regulation. By extending our understanding of Dll4 in Treg cell stability and function, our results 
may provide a road for future translational research leading to a better therapeutic strategy. 
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Chapter 4  SMYD3: a Methyltransferase that Supports Dll4-enhanced Treg Cell 
Differentiation 
4.1 Abstract 
Notch ligand Dll4 has been shown to regulate CD4 T cell differentiation, including Treg cells. 
Epigenetic alterations, which include histone modifications, are critical in cell differentiation 
decisions. Recent genome-wide studies demonstrated that Treg cells have increased tri-
methylation on histone H3 at lysine 4 (H3K4me3) around the Treg master transcription factor, 
Foxp3 loci. Here we report that Dll4 dynamically increased H3K4 methylation around the Foxp3 
locus that was dependent upon up-regulated SET and MYDN domain containing protein 3 
(SMYD3). Dll4 promoted Smyd3 through the canonical Notch pathway—RBP-Jk in iTreg cells 
during in vitro differetiation. Smyd3 were enriched in TGF-b dependent Th (iTreg and Th9) in 
vitro, and more abundant in lung than lymphoid tissue (thymus and spleen). Deletion of Smyd3 in 
CD4 cells perturbed IL-17A cytokine production and exacerbated RSV immunopathology in vivo.  
Using genome-wide unbiased mRNA sequencing, a novel set of Dll4- and Smyd3-dependent 
differentially expressed genes was discovered (e.g. Lag3). Together, our data demonstrate a novel 
mechanism of Dll4/Notch-induced Smyd3 pathway activation that regulates and stabilizes 
immunomodulatory environment in viral infections.  
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4.2 Introduction 
Many infectious and chronic inflammatory diseases are characterized by inappropriate or 
dysregulated CD4+ T cell immunity. CD4+ T cell immunity underlies successful immune 
responses with diverse cytokine expression profiles and distinct effector functions. Naïve CD4 T 
cells differentiate into subsets of CD4 T helper cell (Th) upon T cell receptor activation, cell 
associated co-stimulatory proteins, and cytokine stimulation. The different Th subsets, type 1 Th 
(Th1), type 2 Th (Th2), IL-17–producing Th (Th17), IL-9-producing Th (Th9) cells, produce a 
unique set of cytokines (IFN-g for Th1; IL-4, IL-5, and IL-13 for Th2; IL-17A for Th17, IL-9 for 
Th9).  Treg cells, especially iTreg cells, constrain airway allergic inflammation 154,234,235 and 
immunopathology upon RSV infection39,41,42. Foxp3 is the master transcription factor of Treg cells 
that is induced by TCR activation in the presence of TGF-b 150,236. Both transcription factors and 
post-translational modifications can fine-tune the activity of Foxp3 promoter or conserved non-
coding DNA sequence (CNS) 1, 2, 3 to control the expression of Foxp3 and the function, 
composition, and stability of Treg populations 140,236.  
 Post-translational modifications that alter gene expression without changing the bases of 
DNA sequence, are called “epigenetic modifications”. Epigenetic alterations, including histone 
modifications, DNA methylation, chromatin remodeling, and microRNAs, are indispensable for 
optimized Th differentiation 176,177.  One of the permissive epigenetic marks—histone 3 lysine 4 
tri-methylation (H3K4me3) is enriched around the activated gene promoters while the suppressive 
marks—H3K27me3 are removed compared to uncommitted naïve CD4 T cells 185. In Treg cells, 
H3K4me3 are mostly enriched around Foxp3 CNS1 and its promoter but not as significantly 
around CNS2 and CNS3 140. Another mechanism, DNA methylation on CpG motif was reported 
to contribute to Foxp3 instability 160,162, while Tet methylcytosine dioxygenase 1(TETs) facilitated 
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CpG motif de-methylation and enhanced Foxp3+ Treg cell stability 183. Histone modification by 
Ezh2 demonstrated that removal of H3K27me3 around Foxp3-bound genes stabilizes Treg cell 
identity 186 and enhances its suppressive function in response to inflammation187. Our lab 
previously identified that SMYD3, which is a H3K4 di- and tri-methyltransferase 189, was induced 
by TGF-b and supported iTreg cell differentiation to lessen immunopathogenesis in pulmonary 
viral infections 192. In a separate study we have also identified that Dll4/Notch leads to stabilization 
of the iTreg phenotype in vivo and in vitro120. The present studies further extend those earlier 
findings by identifying the Notch-mediated epigenetic mechanism in regulating Treg cell function.  
 Notch signaling is well-conserved throughout metazoans and orchestrates T cell 
differentiation decisions237–239. In CD4 T cells, Notch signaling influenced CD4 T helper cell 
differentiation, including Th1, Th2, Th17, and Th9 cells, by directly initiating Th signature 
transcription. Compelling evidence showed that Notch activation directly drives Th programs in 
part through downstream transcription complex binding. In Th1, Notch1 directly interacts with 
Ifng CNS22 to cooperate with T-bet 76; in Th2 cells, Notch1 and its downstream DNA-binding 
transcription factor—RBP-Jk—directly interact with Il4 and Gata3 promoters during Th2 
differentiation81; RBP-Jk interacts with Il17a and Rorc promoter 87, and with the Il9 promoter 
during Th9 cell differentiation 62. Together, Notch orchestrates multiple Th differentiation 
pathways 76. The mechanism of Notch in Treg cell differentiation is more complex. Notch directly 
induces Treg master transcription factor, Foxp3, through RBP-Jk in iTreg differentiation 63, while 
constitutively active Notch1 in developed Foxp3+ Treg destabilized peripheral Treg in part 
through CpG motif methylation on Foxp3 CNS2 70. These studies are the first to demonstrate that 
Notch and its ligand regulates iTreg differentiation through an epigenetic mechanism.  
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 Here we report that Notch signaling through its ligand Dll4 directly regulated Smyd3 
expression during iTreg differentiation leading to H3K4me3 around the Foxp3 locus to stabilize 
Foxp3 expression. Dll4 inhibition and/or Smyd3 deletion introduced cytokine dysregulation 
including increased IL-17A and decreased IL-10 to confer immunopathology upon viral infection. 
Using genome wide RNA sequencing, we further identified Treg cell signature genes —including 
Lag3 and Tgm2—that are regulated by Dll4 and Smyd3. These latter studies also strongly suggest 
that these same signals have an overall effect on the immune environment by altering both Foxp3+ 
Treg and Foxp3- T cells. Together, our study reveals a novel pathway—Dll4àSmyd3—that can 
control Treg differentiation and function and affect the overall immune environment.  
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4.3 Results 
4.3.1 Notch ligand Dll4 promotes gene activation and histone modification around the 
Foxp3 gene during iTreg cell differentiation in vitro 
Dll4/Notch activation through the canonical Notch signaling pathway enhances Treg 
differentiation by stimulating Foxp3 gene expression 63,120. H3K4me3 is a permissive histone mark 
that represents gene activation and is enriched around the Foxp3 locus in Foxp3+ Treg cells 180,240. 
Here we hypothesized that Dll4 may enrich H3K4me3 around the Foxp3 gene to enhance iTreg 
differentiation. Given that iTreg differentiation accompanies Foxp3 expression while Th0 
activation lacks Foxp3 expression, we examined the role of Dll4 on H3K4me3 marks around the 
Foxp3 promoter and functional enhancers, CNS1, CNS2, and CNS3, in iTreg compared to Th0 
cells. Using chromatin immunoprecipitation (ChIP), the data showed that Dll4 stimulation drove 
the enhancement of H3K4me3 around Foxp3 promoter as well as in CNS1, CNS2 and CNS3 at 72 
hours specifically in iTreg but not in Th0 cells (Figure 4.1A). To characterize the relative 
enrichment of H3K4 mono-methylation (H3K4me) and H3K4me3 in the Foxp3 promoter and 
enhancers during early iTreg differentiation, we immunoprecipitated both H3K4me and H3K4me3 
at 48 hours of iTreg differentiation. Dll4 decreased H3K4me while it increased H3K4me3 around 
the Foxp3 promoter as well as in CNS1, 2, and 3 regions (Figure 4.1B). Foxp3 induction in the 
presence of TGF-b-Smad3 is dependent on CNS1 150,154,236, allowing us to focus on the dynamics 
of H3K4me3 on Foxp3 CNS1. Dll4 stimulation first decreased but then inversely increased 
H3K4me3 at 48 and 72 hours post differentiation at the CNS1 enhancer (Figure 4.1C). These data 
suggested that Notch ligand Dll4 activation changed the H3K4me3 around Foxp3 promoter and 
its functional CNS1 enhancer during iTreg differentiation.  
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Figure 4.1 Dll4 enriches H3K4me3 around Foxp3 promoters and consensus-non-coding 
sequences (CNS)1, 2, 3 
A. 2X106  of naïve CD4 T cells were skewed toward Th0 or iTreg cell differentiation with or 
without Dll4 stimulation in vitro. ChIP was performed to detect H3K4me3 around the 
Foxp3 promoter and CNS 1, CNS2 and CNS3 after 72 hours. 
B. Changes of H3K4me and H3K4me3 by Dll4 stimulation during iTreg cell differentiation 
was detected at 48 hours of skewing.  
C. H3K4me3 kinetics at Foxp3 CNS1 after 6 hours, 24 hours, 48 hours and 72 hours post 
iTreg cell differentiation were measured with or without Dll4 stimulation in vitro.  
Data represent mean ± SEM. Data were from one experiment representative of two to 
three experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired 
two-tailed t-test)  
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4.3.2 Dll4 promoted SMYD3 during iTreg cell differentiation 
The addition of methyl groups on H3K4 is mediated by histone lysine methyltransferases 241. 
Therefore, we hypothesized that Dll4 would regulate an epigenetic enzyme to catalyze H3K4me3 
around the Foxp3 locus during iTreg cell differentiation. To investigate if Dll4 up-regulated any 
epigenetic enzymes in iTreg cells, especially histone methyltransferases, we performed an 
epigenetic enzyme PCR array to compare the Dll4-stimulated gene profile in iTreg differentiation 
at 48 hours. The array analysis indicated that Smyd3 was the most up-regulated candidate in the 
iTreg+Dll4 activation (Figure 4.2A). It was also the most highly up-regulated methyltransferase 
when examining all methyltransferases in the array across multiple experiments (Figure 4.2B). 
Smyd3 expression was significantly increased by Dll4 stimulation in iTreg cells but not in Th0 or 
in unstimulated iTregs as determined by RT-PCR (Figure 4.2C). Consistently, Dll4 stimulation 
also increased SMYD3 protein expression at 48 hours (Figure 4.2D). These data suggested that 
Dll4 facilitates Smyd3 expression in iTreg cell differentiation in vitro.  
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Figure 4.2 Dll4 up-regulates SMYD3 methyltransferase in iTreg cell differentiation 
A. The expression of 87 epigenetic enzymes in epigenetic PCR array (SA Bioscience, 
PAMM-085) were measured in DLL4-stimulated iTreg cells compared to Th0 cells after 
48 hours of skewing. Fold changes were indicated with a heatmap. The following genes 
were either up or down-regulated more than two-fold: Dnmt1 (A11), Hdac9 (C7), Nek6 
(E2), Smyd3 (G4), Ube2a (G7), Usp21 (G11) 
B. All the methyltransferases in the PCR array are shown. The arrow indicated Smyd3 as the 
most-expressed methyltransferase in vitro 
C. Smyd3 expression levels were measured after 24 hours of Th0 and iTreg cell 
differentiation with or without Dll4 activation in vitro. 
D. Smyd3 expression time course shows the relative expression of Smyd3 normalized to 
Gapdh and then compared to Th0 cell control at every time point.  
E. SMYD3 expression was blotted after 48 hours of iTreg cell differentiation with or 
without Dll4 stimulation.  
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. PCR array is one-time experiment. * P<0.05; ** P<0.005; *** P<0.0005; NS: 
no significance (unpaired two-tailed t-test)  
 
4.3.3 Intracellular Notch signaling promoted SMYD3 in a RBP-Jk dependent manner 
during iTreg differentiation 
To further investigate if Dll4-upregulated Smyd3 expression is Notch-dependent, we used CD4-
specific Rbpj knockout mice and CD4-specific dominant-negative MAML1 mice (DNMAML) 
that deleted canonical Notch transcription factor and inactivated intracellular Notch signaling 
activation, respectively. The expression of Smyd3 was significantly decreased in Rbpj-/- CD4 T and 
DNMAML CD4 T cells in Dll4-stimulated iTreg differentiation (Figure 4.3A~B), suggesting that 
Smyd3 expression is dependent on intracellular Notch signaling activation. To investigate if Smyd3 
is a potential target gene of canonical Notch signaling, we examined the Smyd3 promoter and 
found 5’-TGGGAA-3’ RBP-Jk consensus binding sites 87,242 upstream of Smyd3 transcription start 
site (TSS) using in silico analysis (Figure 4.3C). We performed a promoter walk, and 
representative primer sets 0 (P0) and P2 showed that RBP-Jk directly bound to the Smyd3 promoter, 
with Dll4 stimulation further enriching RBP-Jk binding at 6 hours of early iTreg differentiation 
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(Figure 4.3C). Together, these data demonstrated that Dll4 and intracellular Notch signaling 
facilitated Smyd3 expression in iTreg differentiation.  
   
Figure 4.3 Dll4 promotes Smyd3 expression through canonical Notch and RBP-Jk in iTreg 
differentiation 
A. Naïve CD4 T cells were isolated from CD4-specific Rbpj knockout mice or wt un-floxed 
littermate controls. Activated (Th0) or iTreg differentiation with or without Dll4 were 
performed. After 48 hours, CD4 T cells were harvested and Smyd3 were measured. 
B. Naïve CD4 T cells were isolated from wt B6 or CD4-specific DNMAML mice. Smyd3 
were measured after 48 hours of iTreg differentiation+Dll4 stimulation in vitro. 
C. 2X106  of naïve CD4 T cells were isolated from wild type B6 mice. After iTreg 
differentiation with or without Dll4 stimulation for 6 hours, RBP-Jk were precipitated 
and RBP-Jk-bound DNA sequence were PCR with Smyd3 primer P0 and P2.  
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. PCR array is a one-time experiment. * P<0.05; ** P<0.005; *** P<0.0005; NS: 
no significance (unpaired two-tailed t-test)  
 
4.3.4 SMYD3 was enriched in TGF-b mediated T helper cells differentiation 
SMYD3 is enriched in TGF-b-induced iTreg cells 190. To further investigate the relative 
expression level of SMYD3 in differentiated T helper cells subsets (Th), we skewed naïve T cells 
to Th1, Th2, Th17, Th9, iTreg and IL-27 Treg1. Here we found that both iTreg and Th9 (TGF-
b+IL-4) had enriched SMYD3 protein levels, but not much was expressed in naïve CD4, Th0, 
Th1, Th2, Th17, and IL-27 cells in vitro (Fig 3A). 
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Figure 4.4 SMYD3 is enriched in iTreg and Th9 only slightly in activated CD4 T cells (Th0) 
and Th1, Th2, Th17, and IL-27 type 1 regulatory T cells (Treg1) 
 
4.3.5 Dll4-facilitated Foxp3 expression was SMYD3-dependent 
Since Dll4 upregulates Foxp3 expression during iTreg differentiation and further, that Dll4/Notch 
upregulated Smyd3, we hypothesized that Dll4 and Smyd3 cooperatively upregulated Foxp3. We 
first confirmed that Cre+ cKO expressed minimal amount of SMYD3 compared to Cre- controls 
in iTreg cell differentiation at 72 hours (Figure 4.5A). Here the data showed that Dll4 facilitated 
Foxp3 expression in Cre- control, whereas deletion of Smyd3 decreased Foxp3 expression in the 
presence of Dll4 at 48 hours during iTreg cell differentiation (Figure 4.5B). Consistent with wt 
B6 mice, Dll4 stimulation up-regulated H3K4me3 around the Foxp3 promoter as well as in CNS1, 
2, and 3 in Cre- control, but Dll4 did not increase H3K4me3 in Cre+ Smyd3 knockout CD4 T cells 
(Figure 4.5C).  These data suggested that Smyd3 mediated Dll4-enriched H3K4me3 around Foxp3 
regulatory elements—promoter, CNS1 and CNS2. Thus, Dll4 appears to support Foxp3 expression 
through induction of SMYD3 leading to histone modification and expression of Foxp3.  
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Figure 4.5 Dll4-enhanced H3K4me3 enrichments are SMYD3 dependent 
A. 106 naïve CD4 T cells from Cre- control or Cre+ CD4-specific SMYD3 conditional 
knockout (cKO) were differentiated to iTreg cells. After 72 hours, SMYD3 levels were 
quantified by Western blotting. 
B. Smyd3 mRNA levels were measured in iTreg cells and Dll4-stimulated iTreg cells post 
48 hours.  
C. 2*10^6  of naïve CD4 T cells from Cre- control with or without Dll4 stimulation or Cre+ 
CD4-specific SMYD3 were differentiated to iTreg cells. After 72 hours, H3K4me3 was 
immune precipitated, and Foxp3 promoter and CNS1, 2, 3 were qPCR quantified 
compared to input control 
 
Next, we determined if Smyd3 was also involved in Dll4-facilitated iTreg cell differentiation and 
maintenance by flow cytometric analysis of the differentiated cell populations. Dll4-increased 
Foxp3+ iTreg cells were compromised in Smyd3 cKO mice at 3 days post iTreg differentiation 
(Figure 4.6) and continued to be impaired after 6 days both with and without Dll4 with no 
increase in Treg cell development in the presence of Dll4 without SMYD3 (Figure 4.7). 
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Figure 4.6 SMYD3 modulates and supports Foxp3+ iTreg primary differentiation in vitro 
106 of naïve CD4 T cells from Cre- control or Cre+ SMYD3 cKO were activated (Th0) or 
differentiated to iTreg with or without Dll4. After 72 hours of skewing, Foxp3 and CD25 
were labeled and quantified by flow cytometry 
 
 
Figure 4.7 SMYD3 maintains Dll4-enhanced Foxp3+ iTreg cells after incubation with IL-2 
in vitro  
106 of naïve CD4 T cells from Cre- control or Cre+ SMYD3 cKO were activated (Th0) or 
differentiated to iTreg cells with or without Dll4. After 72 hours of skewing, both Th0 
and iTreg were rested in IL-2 (10 ng/mL) for another 72 hours. Foxp3 and CD25 were 
detected and quantified by flow cytometry. 
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired two-tailed 
t-test). 
 
        To further explore if the methyltransferase function of SMYD3 is responsible for iTreg cell 
differentiation and maintenance, we collaborated with Epizyme to test their SMYD3 inhibitor—
EPZ030456. This small molecule inhibitor is specific to SMYD3 and has an IC50=40nM. After 
testing that 50 nM and 200 nM didn’t affect T cell viability, we performed H3K4me3 ChIP around 
the Foxp3 locus. Both 50 nM and 200 nM EPZ030456 decreased H3K4me3 on the Foxp3 promoter, 
CNS1, and CNS2 (Figure 4.8A and data not shown), similar to Smyd3 knockout mice shown in 
Figure 4.5. Surprisingly, both 50 nM and 200 nM of EPZ030456 Smyd3 inhibitor did not affect 
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iTreg cell differentiation at 3 days (data not shown). Since previous reports indicatethat epigenetic 
changes regulate long-term and later cell differentiation decisions, we turned to a longer regimen 
where we inspected the differentiation based on cell proliferation status. When we performed 6 
days iTreg maintenance regimen with Smyd3 inhibitor at day 0 and day 3, the inhibitor increased 
Foxp3- undifferentiated cells in slowly-proliferative generations (labeled as CTV generation 1 to 
5) (Figure 4.8B), especially in Dll4-exposed iTreg (Figure 4.8C). These data indicate that Smyd3 
methyltransferase activity indeed catalyzed H3K4me3 around the Foxp3 gene but only slightly 
modulated iTreg differentiation.  
 
 
 
Figure 4.8 SMYD3 inhibitor EPZ030456 decreases H3K4me3 around Foxp3 locus, 
increases Foxp3- undifferentiated and slowly proliferative CD4 T cells in vitro 
A. 2*10^6 naïve CD4 T cells were differentiated toward iTreg phenotype for 72 hours in the 
presense of DMSO alone or with SMYD3 inhibitor—EPZ030456. H3K4me3 (abcam) or 
control IgG were immunoprecipitated with ChIP and the Foxp3 loci were amplified.  
B. 2*10^5 naïve CD4 T cells were incorporated with Cell Trace Violet (CTV) and were 
differentiated toward the iTreg phenotype with or without Dll4 and/or SMYD3 inhibitor for 
72 hours. The iTreg cell culture were maintained in IL-2 (10 ng/mL) and fresh SMYD3 
inhibitor as above. After another 72 hours, Foxp3- undifferentiated G1-G4 slowly 
proliferative populations were gated 
C. Foxp3- undifferentiated CD4 gated in B. were quantified.  
 
 
 
After knowing that SMYD3 itself supports iTreg differentiation, we next determined whether 
SMYD3 in CD4 support Treg function, both in peripheral nTreg and iTreg cells. In vivo pTreg 
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were enriched by sorting viable CD4+CD25+ Treg cells from inguinal lymph nodes (Figure 4.9A), 
and CD45.2 peripheral nTreg were co-cultured with CD45.1 naïve CD4 T cells labeled with CTV. 
After 72 hours of stimulation with anti-CD3/anti-CD28 beads, we measured Treg suppression by 
gating proliferation of naïve T cells. The data showed that Smyd3 knockout nTreg cells have 
similar functions to control cells, suggesting that Smyd3 did not control nTreg cell function 
(Figure 4.9B).  Instead, Smyd3 KO iTreg cells were less functional at 1:1 Treg: naïve T culture 
(Figure 4.9C). There was a greater percent of CTV-diluted CD45.1 responder cells when co-
cultured with Cre+ Smyd3 KO iTreg cells(Figure 4.9 D). These data suggest that Smyd3 
moderately contributes to  iTreg cell function in vitro.  
 
Figure 4.9 SMYD3-depleted iTreg are less suppressive in an in vitro suppression assay 
A. DAPI-CD4+CD25+ viable nTreg and iTreg cells were flow sorted. 
B. 2.5*10^4 CD45.1+ naïve CD4 T cells were labeled with CTV and co-cultured with 
serial-diluted nTreg cells. 2.5*10^4 of anti-CD3/anti-CD28 mouse T cell activator beads 
were added to cell culture. After 72 hours, CTV dilution in viable CD45.1 responders 
were gated to represent Treg cell suppression ability. 
C. iTreg cells were cultured as described in Figure 4.7. 2.5*10^4 CD45.1+ naïve CD4 T 
cells were labeled with CTV and co-cultured with serial-diluted iTreg cells. 2.5*10^4 of 
anti-CD3/anti-CD28 mouse T cellactivator beads were added in co-culture. After 72 
hours, CTV dilution in viable CD45.1 responders were gated to represent Treg 
suppression ability 
D. CTV in CD45.1 T cell responders are shown. The groups were: T cell responder only 
without mouse T cell activator (CTV unstimulated), T cell responder only with mouse T 
cell activator (T responder only 0:1), T cell responder+ Dll4-treated Cre- iTreg + mouse 
T cell activator (Cre-), T cell responder+ Dll4-treated Cre+ iTreg+ mouse T cell activator 
(Cre+).  
Data represent mean ± SEM. Data were from one experiment representative of two 
experiments with 3 to 5 mice per time point, with samples from each mouse processed and 
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analyzed separately. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired 
two-tailed t-test)  
 
        As Figure 3.1 shows, RSV infection in lung enriches Dll4 on DC. To examine if RSV 
infection in the lung is a good model to study Smyd3 function, we first measured Smyd3 
expression in lung versus other lymphoid tissues. Lungs have much higher baseline expression of 
Smyd3 than thymus and spleen (Figure 4.10A). And RSV infection further induced Smyd3 
expression in the lungs at both 4 dpi and 6 dpi (Figure 4.10B). These results imply that RSV 
infection in lungs could induce not only Dll4 but Smyd3 and thus, is an optimal model to study 
their regulation in pTreg in vivo.  
 
 
Figure 4.10 Smyd3 is enriched in lung non-lymphoid tissue and is further up-regulated by 
RSV infection 
A. Smyd3 expression in primary lymphoid organ--thymus, secondary lymphoid organ--
spleen, and non-lymphoid tissue--lung from uninfected wt B6 mice were measured. N=4 
B. Smyd3 expression in lungs of uninfected naïve mice and i.t. RSV infected mice at 4 dpi 
and 6 dpi was measured. N=4 
 
4.3.6 Smyd3 lessened RSV lung immunopathology and regulated Treg cells and cytokine 
production in CD4 T cells 
    Next we investigated Smyd3 function in pTreg cells, CD4 cytokines and RSV pathology. Using 
Smyd3 cKO, more mucin-positive staining and globlet cell hyperplasia in lung was observed, 
indicating the more severe immunopathology in cKO at 8dpi (Figure 4.11A), while the viral 
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clearance was maintained in Cre+ knockout post RSV infection (data not shown). Smyd3 cKO had 
decreased CD25+Foxp3+ Treg cells (Figure 4.11B) as described 190. Treg cell functional markers 
including CTLA-4, OX40 and ICOS were not changed between Cre- control and Cre+ Smyd3 
cKO mice at both 6 dpi and 8 dpi (data not shown). Granzyme B in both Foxp3+ Treg cells and 
CD8 T cells was not altered at 8 dpi (data not shown). However, deletion of Smyd3 led to increased 
IL-17A in mLN after RSV restimulation (Figure 4.11C). Type 1 cytokine IFNg was unchanged, 
but type 2 cytokine IL-5 was increased in Smyd3 cKO (Figure 4.11D~E). Both Foxp3+ Treg and 
Foxp3—IL-10-producing type 1 Treg have been shown to be suppressive in RSV infection 39,50,51. 
Here we further found that Smyd3 cKO mice secreted less anti-inflammatory cytokine IL-10 in re-
stimulated mLN at 8 dpi (Figure 4.11F). These data suggested that Smyd3 in T cells supported 
regulatory cells phenotype and key cytokines to alleviate RSV immunopathology.  
 
Figure 4.11 Smyd3 in T cells impedes RSV immunopathology 
A 
B C D E F
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A. CD4-specific Smyd3 knockout (Cre+ Smyd3 cKO) and Cre- littermate control were i.t 
infected with RSV. PAS staining of formalin-fixed lung section from 8 dpi. Bar, 100 µm. 
indicates the detection of mucin. N=5~6. 
B. Percent of viable CD25+Foxp3+ Treg cells in lungs were gated and quantified at 8dpi.  
C- F. mLN cells were harvested at 8dpi and re-stimulated with RSV for 48 hours. The 
following cytokines were measured in the supernatants: C.) IL-17A; D.) IFN-g; E.) IL5; 
F.)IL10.  
Data represent mean ± SEM. Data were from one experiment representative of two 
experiments with 4 to 6 mice per group, with samples from each mouse processed and 
analyzed separately. * P<0.05; ** P<0.005; *** P<0.0005; ND: not-detectable; NS: no 
significance (unpaired two-tailed t-test)  
	
4.3.7 Notch and Smyd3 promote Il10 and inhibit Il17a in vitro during iTreg cell 
differentiation 
To better understand if Dll4 and intracellular Notch regulated IL-10 and IL-17A in iTreg cells, 
naïve CD4 T cells from wild type B6 mice were skewed towards iTreg cells. Dll4 stimulation 
enhanced Il10 expression and inhibited Il17a at 24 hours post iTreg differentiation, but the 
observations were reversed using a pan-Notch inhibitor of gamma-secretase (gsi) (Figure 
4.11A~B). More specifically, naïve CD4 T cells from Notch-inactivated DNMAML and canonical 
Notch deleted Rbpj cKO mice secreted less IL-10 in the presence of Dll4 (Figure 4.11C) and more 
IL-17A in iTreg+Dll4 conditions (Figure 4.11D). To further understand if Dll4 regulated Il10 and 
Il17a expression in a Smyd3 dependent manner, naïve CD4 T cells from Cre+ Smyd3 cKO and 
Cre- littermate controls were activated toward iTreg phenotype. Dll4-upregulated Il10 expression 
was partially Smyd3-dependent during primary iTreg diffentiation (Figure 4.11E), and Smyd3 
inhibited Il17a expression in primary iTreg cell differentiation (Figure 4.11F). Finally, we 
determined whether the presence of Smyd3 regulated IL-17A secretion using a Th17 plasticity 
assay. After resting, Dll4-activated iTreg cultures were re-stimulated under Th17 skewing 
conditions. Dll4-exposed Smyd3 cKO secreted more IL-17A than Cre- controls (Figure 4.11G). 
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These data indicate that Dll4 and Smyd3 cooperatively promoted Il10 and inhibited Il17a. In 
contrast, since Smyd3 deleted T cells have significant increases in IL-17 and Dll4 reduces the level 
of IL-17 in both WT and Smyd3 KO, the two signals may also have differential effects on IL-17 
regulation.  
 
Figure 4.12 Intracellular Notch and Smyd3 in CD4 T cells support IL-10 production and 
inhibit IL-17A production in iTreg cells in vitro 
A. Naïve CD4 T cells were isolated and incubated with DMSO or 1 µM of gamma-
secretase inhibitor (gsi) and proceed to Th0 or iTreg differentiation with or without 
Dll4 for 24 hours. Il10 mRNA was measured;  
B. Naïve CD4 T cells were isolated and incubated with DMSO or 1 µM of gamma-
secretase inhibitor (gsi) and proceed to Th0 or iTreg differentiation with or without 
Dll4 for 24 hours. Il17a mRNA was measured. 
C. Naïve CD4 T cells from DNMAML mice and Rbpj cKO mice were activated with 
Dll4 for 48 hours. IL-10 production in supernatant was measured. 
D. Naïve CD4 T cells from DNMAML mice and Rbpj cKO were differentiated to iTreg 
cells with Dll4 for 48 hours. IL-17A production in supernatant was measured. 
E. Naïve CD4 T cells from Cre- control or Smyd3 cKO were differentiated to iTreg cells 
with or without Dll4 for 48 hours. Il10 expression was measured;  
F. Naïve CD4 T cells from Cre- control or Smyd3 cKO were differentiated to iTreg cells 
with or without Dll4 for 48 hours. Il17a mRNA was measured.  
G. Naïve CD4 T cells from Cre- control or Cre+ Smyd3 cKO micewere differentiated to 
iTreg cells with Dll4 stimulation for 72 hours then rested in IL-2 (10 ng/mL) for 
another 72 hours. 5*10^5 of viable rested iTreg cells were re-stimulated under Th17 
skewing condition for 72 hours. IL-17A in Th17 re-stimulation culture was measured.  
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Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired two-tailed 
t-test)  
 
4.3.8 Dll4 and Smyd3 regulated gene expression profile in iTreg differentiation 
In the above studies we identified that Dll4 increased Treg cell differentiation as well as promoted 
maintenance of the Treg phenotype that was enhanced by a Smyd3 mechanism. Interestingly, 
Figure 4.12 showed that Notch inactivation and Smyd3 deletion produced changes in Il10 and 
Il17a expression (24 to 48 hours) before Smyd3 protein induction (48 to 72 hours) and Foxp3 
protein dysregulation (72 to 144 hours). Thus, while some of the Treg characteristics were 
enhanced by Dll4/Notch through a Smyd3-dependent mechanism, others were not. Therefore, we 
hypothesized that Dll4 and Smyd3 could regulate additional genes independent of Foxp3 during 
iTreg cell differentiation. To discover novel genes that are regulated by Dll4 and/or Smyd3 
dependent pathways, we performed whole genome RNA sequencing in early iTreg cell 
differentiation (48 hours after skewing). To distinguish the results between four groups, principle 
component analysis (PCA) was performed in DESeq2. Dll4 stimulation introduced substantial 
variance (76%) in gene expression profile, and Smyd3 deletion changed the global gene expression 
on its own but was especially dramatic in the presence of Dll4 (Figure 4.13A). These results 
demonstrated the interdependence of Dll4 and Smyd3. Next, we investigated what genes were 
differentially expressed by Dll4 stimulation. Some of the significantly up-regulated (dots in red) 
or down-regulated (dots in blue) differentially expressed genes (DEGs) were labeled in black text 
(Figure 4.13B). Smyd3 was significantly up-regulated by Dll4 along with several reported Treg 
cell functional genes including Ctla4, Gzmb, Ox40 (Figure 4.13B). Furthermore, Notch-related 
genes (Dtx1, Notch3, Jag2) and anti-inflammatory cytokine Il10 were also up-regulated by Dll4 
(Dtx1: 2.43 fold; Notch3: 1.98 fold; Jag2: 2.77 fold; Il10: 1.42 fold) (Figure 4.13B). Data also 
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identified DEGs that were significantly up-regulated (adjusted p value<0.05 and absolute fold 
change more than two folds) between wildtype iTreg+Dll4 and control iTreg. These differences 
were examined by comparing overlapping Treg cell signature genes 175 and Foxp3-dependent 
genes 174. A venn diagram illustrates the number of genes that were Dll4-stimulated DEGs, Treg 
signature genes, Foxp3-dependent genes, and the number of genes that were in two or even all 
three groups. Results indicate that only 5.3 % of Dll4-stimulated DEGs were also Treg cell 
signature genes, and 3.3 % of these DEGs were Foxp3-dependent (Figure 4.13C). These results 
indicated that the majority of the Dll4-stimulated DEGs were neither Treg-signatures nor Foxp3-
dependent, and that Dll4 stimulation introduced novel DEGs that may have a previously undefined 
role for Treg cells. To get a more informed understanding of the molecular function of Dll4 DEGs, 
we performed gene ontology analysis of the 781 Dll4 DEGs and plotted a treemap. The most 
significant Gene Ontology (GO) term was cytokine activity with the p-value: 1.8*10-8. The p-value 
of each GO term and their area in treemap were in inverse proportion (Figure 4.13D). Together, 
these data revealed that Dll4 not only regulated reported Treg signatures and Foxp3-dependent 
genes but also broadly impacted cytokine responses during differentiation.  To further identify 
specific DEGs that were both regulated by Dll4 stimulation and Smyd3, we normalized the counts 
and did unsupervised cluster with the Pearson distribution of a heatmap showing the Z-score of 
DEGs. There were 95 DEGs that were significantly [BH adjust p-value (padj)<0.05] regulated 
with a greater than 2 fold change (log2FC > 1) in Dll4 stimulation, and down-regulated more than 
1.5 fold (log2FC < -0.6) in Smyd3 knockout mice (Figure 4.13E). Heatmap analysis then clustered 
with row Means identified the top 20 DEGs. Using this analysis, 2 Treg signature genes, Tgm2 
and Lag3, were highly up-regulated by Dll4 stimulation and down-regulated in Smyd3 knockout 
(Figure 4.13E). Interestingly, Notch target gene Deltex1 (Dtx1) was also decreased in Smyd3 
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depletion.  These data uncovered a new set of DEGs that were Dll4 and Smyd3 dependent. These 
results will help us further define functional gene differences in future studies. 
 
Figure 4.13 Smyd3 deletion changes gene expression profile in iTreg cells in the presence of 
Dll4 stimulation 
A. Principle-component analysis of RNA-seq data sets of iTreg cells from Cre- control or 
Cre+ Smyd3 cKO, with or without Dll4 stimulation, was assessed using the top 500 
genes with the highest variance. Each symbol represented a single mouse. Each group 
have three biological triplicates.  
B. Volcano plot showed the differentially expressed genes (DEGs) in control iTreg+Dll4 
over control iTreg cells; red dots indicated genes that were significantly (BH-adjusted p-
value < 0.05) up-regulated by Dll4 more than 2 fold (log2FoldChange>1), and blue dots 
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represent genes that were significantly down-regulated by Dll4 more than 2 fold. y-axis 
represents the significance of the differential analysis by showing -log10(BH-adjusted p-
value).  
C. Venn diagram demonstrated the overlap between current Dll4-regulated DEGs and 
published dataset of Treg signatures and Foxp3-dependent genes. 
D. Gene Ontology (GO) of un-overlapped Dll4-regulated DEGs (781 genes). Treemap 
showed the significant GO term with False-discovery-rate (FDR)-adjusted global P value 
< 0.05. P value is inversely proportional to area for each GO term. 
E. Normalized expression of all the DEGs that were significantly up-regulated by Dll4 
stimulation more than 2.00 fold, and down-regulated more than 1.51 fold by Smyd3 
deletion. Heatmap presents Z-score in a dendrogram cluster by Pearson distribution and 
ranked based on row Means. Top 20 DEGs and Deltex1 are indicated.  
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4.4 Discussion 
Previous studies showed that infection and inflammation-experienced Treg cells were more stably 
maintained, and they acquired changes in chromatin modifications correlated with gene expression 
profiles 243. Chromatin modifications contribute to long-term responses of Treg cell differentiation, 
subset specification, and cytokine-producing potential, such as histone 3 lysine 4 methylation and 
its methylase 188, But how infection and environmental cues epigenetically instruct Treg cell 
differentiation is relatively undefined. Our labs and others have previously identified that Notch 
ligand Dll4 was induced during pulmonary infection and inflammation to enhance Treg cell 
differentiation 120,244. Here we report one specific methyltransferase, SMYD3 189,245, that could be 
directly regulated by Dll4/Notch. The present study demonstrates several novel findings and 
concepts: 1) Epigenetic enzymes are a part of the mechanism by which RSV infection modifies 
CD4 T cells lineage specification, including Treg cell differentiation; 2) Dll4/Canonical Notch 
signaling directly facilitates SMYD3 expression in vitro and in vivo during RSV infection; 3) Dll4 
stimulation directed gene activation epigenetic mark, H3K4me3, around Foxp3 functional 
promoters and enhancers that is SMYD3 dependent; 4) Dll4 confers cytokine expression changes 
in Treg cells, and SMYD3 regulates additional gene expression in the presence of Dll4. Together, 
our data unravel the broad impact of Dll4/Notch in Foxp3+ Treg cells and have identified a novel 
stabilization mechanism through methyltransferase SMYD3-mediated histone modification.  
 SMYD3 was reported to be regulated by estrogen receptor (ER), androgen receptor (AR) 
and TGF-b 190,196,200,246. Here we reported another novel regulatory signal—Notch. It is noteworthy 
that Dll4 stimulation and intracellular Notch inactivation alone does not activate Smyd3 expression 
in Th0 cells, suggesting that iTreg cell environmental cues including TGF-b and/or IL-2 are 
required. One explanation is intracellular Notch inactivation inhibited TGF-b1 dependent Foxp3 
  85 
expression since Smad3 and RBP-Jk together bind to Foxp3 promoter 63. Given that Smad3 binds 
to the Smyd3 promoter 190 and the present study also showed RBP-Jk binding on the Smyd3 
promoter, these data suggest that TGF-b signaling and canonical Notch pathways may 
cooperatively facilitate Smyd3 expression.  
 Treg suppression is tailored to fit in specific tissue and inflammatory settings using 
multiple suppressive mechanisms. For example, Foxp3/T-bet could suppress Th1 effector 
responses 247, Foxp3/IRF4 suppresses Th2165, and Foxp3/STAT3 suppresses Th17 167. But little is 
known about the direct role of Foxp3 for Treg cell specification. The RNA-seq results showed that 
Ifng was up-regulated more than 16 fold by Dll4 in iTreg cells, suggesting that Dll4 stimulation 
provided a Th1-like profile in iTreg differentiation similar to previous observations in Th1 
differentiation 69,248,249. Although Dll4 neutralization did not significantly perturb IFN-g secretion 
in mLN post RSV infection, here we found that it decreased Ifng in Foxp3-eGFP+ Treg while Ifng 
in eGFP- Tconv was increased. These in vitro and in vivo data suggest a novel paradigm that Dll4 
may favor a Th1-like suppressive program in Treg cells. It would be intriguing to further 
investigate if Dll4 regulated effector T cell cytokine production through T-bet+Foxp3+ Th1-like 
Treg cells.  This program may have a significant advantage in a viral infection, such as RSV, where 
IFN-mediated programs are required for viral clearance yet control more pathogenic Th2 and Th17 
responses necessary to protect tissue function. 
 Besides Foxp3+ Treg cells, the RNA-seq results suggested that Dll4 stimulation promote 
a substantial amount of DEGs (819, 96.7% of total Dll4 DEGs) that are not Foxp3-dependent. The 
RNA-seq results further showed two other Dll4 and Smyd3 dependent gene candidates, namely 
Tgm2 and Lag3. Tgm2 encodes the TG2 protein that covalently crosslinks latent TGF-b1-binding 
protein and controls TGF-b1 maturation and activity 250,251 and therefore increases TGF-b1 mRNA 
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levels 252. In cancer cells, TGF-b-induced Tgm2 promotes epithelial to mesenchymal transition 
(EMT) 253,254. These latter studies suggest that Dll4/Notch and Smyd3 may reinforce the positive 
feedback loop of TGF-b signaling to facilitate iTreg cell differentiation. Another Treg signature 
gene that was shown to be Dll4 and Smyd3 dependent was Lymphocyte activation gene 3 (Lag3). 
Lag3 is required for maximal regulatory function of CD25+Foxp3+ Treg cells 255 and is a 
biomarker for IL-10 producing Treg1 cells that enhance suppressor function to lessen mucosal 
inflammation and autoimmunity 256,257. The present study also found that both Dll4 and SMYD3 
supported IL-10 production in vitro and in vivo during RSV infection, together suggesting that 
Dll4 and SMYD3 may promote Treg1 functional markers to support an overall tolerogenic 
environment along with Foxp3+ Treg cells. Future studies need to be performed to dissect the 
mechanism of Dll4/Notch and Smyd3 in Tgm2 and Lag3 regulation. Since Lag3 is a checkpoint 
inhibitor now targeted in cancer immunotherapy trials, it will be exciting to investigate the efficacy 
of targeting Smyd3 in Notch-active cancers, including lymphomas and leukemias that have Notch 
activation signals.   
        Together, these studies offer new and exciting data that demonstrate the role of a central and 
conserved developmental pathway, Notch, which promotes Treg cell differentiation through a 
SMYD3 mediated epigenetic mechanisms that includes not only direct but indirect effects on 
Foxp3 and other critical Treg cell associated genes (Figure 4.14).   
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Figure 4.14: Schematic summary of how Dll4 promoted Smyd3 expression to leverage 
regulatory features of CD4 T cells7 
  
                                               
7 This figure was created by Hung-An (Anna) Ting 
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Chapter 5  Conclusions and Discussion 
5.1 Significance of studying regulatory T cells in RSV pathogenesis         
The high prevalence and pervasive nature of respiratory infections receives a disproportionate 
level of attention from the public. In fact, WHO reported that respiratory infections count for more 
than 6% of the total global burden of disease that count in mortality, morbidity and financial cost  
258,259. Among pulmonary infections, RSV is the most common and often serious infections in 
pediatric clinics because more than 90% of children have been infected before 2 years of age. The 
current effective therapy is supportive care, hydration, and there’s no strong evidence supporting 
the use of any pharmacologic agents such as steroid had little effect. To date, there is no active 
prophylaxis such as vaccine to control this prevalent infection.  Since the exacerbated 
inflammation is not only the clinical manifestation of RSV infection but also the life-threatening 
predisposition in 1960 RSV vaccine trial260, understanding the regulation of RSV 
immunopathogenesis is in a critical unmet need.  
        RSV clinical manifestations of bronchiolitis aren’t driven by viral replication and direct viral 
toxicity but exacerbated immune responses. Scientist tried to scrutinize the reason of vaccine trial 
failure that led to severe exacerbated disease in the 1960’s RSV vaccine using mice260. These 
studies not only showed that a predominant Th2 response resulted, but also showed that the vaccine 
led to a complete absence of Treg cells in the airways, enhanced lung inflammation and augmented 
clinical severity upon RSV infection260. Moreover, increasing the number of Treg cells in the 
airways recruited by IL-27 which is a type 1 Treg-inducing cytokine reversed the enhanced lung 
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inflammation and weight loss261. Recent studies in mice using RSV clinical isolates also 
demonstrate the importance of both Foxp3+ Treg cells and IL-10-producing type 1 Treg cells in 
limiting pulmonary immunopathology (e.g. mucogenic cytokine secretion). These results highlight 
the significance of regulatory T cells in RSV pathogenesis, and inform the follow up question of 
by what mechanism. Knowing how regulatory T cells are regulated may introduce new insights 
for therapeutic development to control RSV immunopathogenesis. 
        Adaptive immunity that includes B cells and T cells is essential for viral clearance. However, 
RSV clearance has been shown to be predominantly dependent on T cells responses262,263. 
Unfortunately, RSV does not mount good T cells memory responses resulting in the possibility of 
secondary re-infection, even with the same strain10. Thus, one conundrum is how are T cell 
memory responses suppressed by RSV. Recent evidence strongly suggests that Foxp3+ Treg cells 
impede memory responses to viral infections264,265. . The studies in this thesis provides new 
insights of how Treg are promoted in primary RSV infection, regulated by Dll4-induced Smyd3. 
By knowing how Treg are regulated during RSV infection, we may be able to more precisely 
control CD4 regulation to mount appropriate and long-term immune memory against RSV re-
infection and shed light on future vaccine development.  
 
5.2 Notch regulation is context-dependent in Foxp3+ Treg cell differentiation and function 
        Treg cell differentiation and suppressive function are regulated by Notch and its ligand Dll4 
in RSV infection, although the results differ in various disease models with no unified mechanism 
concluded. In autoimmune hepatitis, intracellular inhibition of pan-Notch activation using a 
gamma-secretase inhibitor demonstrates the supportive role of Notch in Foxp3+ Treg cell 
development and function63. As we and others have shown Notch induced Foxp3+ Treg cells play 
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a seminal role in allergic airway disease and in a RSV pulmonary infection model 120,244.  In 
contrast, systemic blockade of Notch ligand Dll4 enriches Foxp3+ Treg numbers and function in 
autoimmune encephalitis and autoimmune diabetes89,98. We think this inconsistency may arise 
from two underlying conditions of Notch signaling and Treg cell biology: 1. The context-
dependent nature of Notch signaling; and  2. The heterogeneity of Foxp3+ Treg cells.  
        The evidence for context dependent regulation of Treg cells by Notch is supported by 4 
different lines of evidence. First, the expression and the role of the Notch ligands may vary in 
different immune responses. In our RSV infection model, only the Dll4 ligand is up-regulated  and 
its expression peaking at 6 dpi and this occurred mainly on CD11b+ pulmonary DC. Notch ligand 
Dll1 was expressed but not gradually up-regulated by RSV infection, while Jag1 and Jag2 weren’t 
up-regulated and undetectable by flow (Figure 3.1 and data not shown). In contrast, all four Notch 
ligands are expressed on DC in a GvHD model221. Moreover, Dll1/4 are also expressed on 
fibroblastic stromal cells in GvHD266, while Dll1 and Jag1 are reported to be present on 
microglia267,268 that initiate neuroinflammation in EAE. Given that Delta and Jagged elicit distinct 
immune responses69,269, these different combinations of Notch ligand expression patterns present 
in different cell types in different disease scenarios introduce layers of complexity that subverts 
any one-for-all theory of Notch activation in vivo. Second, increasing evidence demonstrates that 
Notch receptor and ligand can be modified by post-translational modifications to fine-tune 
signaling status. For example, Lunatic Fringe (Lfng) which is a glycosyltransferase that adds N-
acetyl glucosamine to O-fucose on the extracellular domain of Notch receptors could inhibit 
Jagged-mediated Notch activation but promoting Dll-mediated Notch activation270,271. In T cell 
development, Notch1, 2 and 3 are all expressed in the thymus but Notch1 is preferentially used to 
interact with Delta like ligands (e.g. Dll4) after Lfng activitiy272.  In an RSV infection, exacerbated 
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allergic airway model, Lfng promotes Dll4-Notch binding and Notch activation for Th2 
responses85. Third, intracellular Notch signaling was maintained in an inactive state. For instance, 
a novel zinc finger protein--LRF--could prevent lineage fate decisions of hematopoietic stem cells 
to T cells either through inhibiting intracellular Notch activation273 or repressing Notch ligand 
Dll4274. Last but not least, unknown mediators in a certain inflammatory environment can 
compensate for the absence of Notch in T cells. For example, DNMAML mice are resistant to 
Leishmania major (type 1 parasite infection) but susceptible to Trichuris muris (type 2 parasite 
infection)58. Together these studies serve as evidence to demonstrate the entanglement of Notch 
signaling in the context of other important aspects (e.g. other signals, cell types, disease) with both 
spatial and temporal layers of regulation.  
        Treg in peripheral lymphoid organ and non-lymphoid tissue (pTreg) consist of not only 
nature-occuring Foxp3+ Treg (nTreg) but induced Treg (iTreg) that were Foxp3- before disease 
on-set. The iTreg constitute 10~30% of the total pTreg that is tissue dependent in vivo275–277. Using 
Foxp3Cre to delete Notch1 or by overexpressing NICD in differentiated Foxp3+ Treg cells, a recent 
study argues that Notch impedes Foxp3+ Treg cell maintenance and function in GvHD70. These 
should not be mis-interpreted since GvHD is mainly prevented by nTreg cells 224,225, not iTreg 
cells due to lineage instability226. Using Neuropilin-1 (Nrp1) to distinguish nTreg versus iTreg 
cells in vivo as described 113–115,227, our finding showed that Dll4 inhibition decreased Nrp1− Treg 
cells during RSV infection (Appendix Figure A.1). Therefore, we speculate that Dll4/Notch may 
have a differential role in nTreg versus iTreg. Additional research needs to be done to test this 
hypothesis.   
 
  92 
5.3 Distinct methods of Dll4 inhibition share similar outcomes in Foxp3 regulation 
        We used two different methods to study the role of Dll4 in regulatory T cells and RSV 
immunopathology. One is systemic neutralization of Dll4 with anti-Dll4 antibody, and another is 
knocking down Dll4 on i.t transferred DC with the following RSV infection. Based on the data 
that RSV infection enriches Dll4 expression on DC but not on other cells types (e.g. alveolar 
macrophages) (Figure 3.1-3.3 and data not shown), we hypothesize that the Dll4 neutralization 
targets DC-presented Dll4 to tamp down Notch signaling activation in CD4 T cells (Figure 3.5C). 
However, we can’t ignore the possibility that other cell types could also present Dll4 that are 
involved in exacerbated RSV immunopathology. In GvHD, our collaborator Maillard lab and 
others found that systemic blockade of Dll ligand decreased GvHD mortality. Surprisingly, 
deletion of Dll1 and Dll4 in the hematopoietic system had minimal effects on T cell pro-
inflammatory cytokines. In contrast, Dll1 and Dll4 deletion in stromal cells impaired donor T cell 
production of IFNg and IL-2 and also impaired protection from GvHD278. With Dll4 neutralization, 
we found decreased development of central Treg cells by Foxp3 MFI and reduced function of 
effector Treg cells by GzmB. To further examine our hypothesis that the Dll4 on DC regulates 
Treg, we sensitized mice into the airway with RSV-infected Dll4-deleted DC versus control DC 
and examined the immune response of re-infection with RSV. Dll4 on DC supported Foxp3 
expression in total Treg populations, both central and effector Treg cells (Figure 3.13). Moreover, 
the absence of Dll4 on DC exacerbated the RSV immunopathology with increased mucus 
production, goblet cells hypertrophy, and mononuclear cell infiltration (Figure 3.13). These 
overlapping results support the notion that indeed, Dll4 on DC support Foxp3 expression and 
suppress RSV pathology. But unlike Dll4 systemic neutralization, we didn’t detect any Th17 cell 
plasticity phenotype in Foxp3+ Treg by sorting Foxp3-GFP+ for Il17a expression or by staining 
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IL-17A+Foxp3+ in Dll4 DC knockdown (data not shown), suggesting that DC-presented Dll4 may 
not involve in Treg-Th17 plasticity. We didn’t find a GzmB+ Treg decrease either in Dll4 
knockdown DC transfer mice. In this experiment, 12 days after transfer of Dll4 knockdown DC 
mice are re-infected with RSV  and sacrificed 8 days later.  Thus, it’s possible that this 20 day time 
point had passed IL-17A peak production and also was involved in the exacerbated responses. 
While our study revealed a novel model that Dll4 on DC sustained Foxp3+ Treg cells and impeded 
RSV immunopathology, future studies need to be performed to further establish the role of Dll4 
on DC in Th17-Treg plasticity and additional aspects of Treg function. 
 
5.4 The role of Dll4 in regulating CD4 T cell co-stimulation and co-inhibition: beyond 
Foxp3+ Treg 
        Previous studies have shown that Notch could regulate T cell co-stimulation, known as signal 
2. First, Notch could directly regulate CD28 expression in T cell acute lymphoma (T-ALL)279. 
Second, several Notch target genes including HES inhibit PTEN expression that is a negative 
regulator of co-stimulation280. Third, Notch/Dll1 boosts the activation of TCR at Double Negative 
stage 3 (DN3) pre-T cell development281,282 and Notch/Dll4 promotes CD4SP naïve T cell 
activation74, both through the same downstream co-stimulation pathway of the PI3K/Akt/mTOR. 
However, the role of Notch and Dll4 in the expression of other co-stimulators and co-inhibitors 
remains elusive. However, Notch regulates co-activator/co-inhibitor in have not been elucidated 
during pulmonary infection.   Here our Figure 4.13 reports multiple co-stimulators and co-
inhibitors that are differentially expressed by Dll4 stimulation during Treg differentiation, 
including co-stimulator OX40 and co-inhibitors CTLA-4, TIGIT, PD-1 and Lag3. These 
molecules are highly expressed on Treg cells in the homeostatic state and have been called “Treg 
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functional markers”, while they are also functionally present in conventional Foxp3- CD4 SP 
cells283–285. Binding of OX40 and PD-1 to their ligands (OX-40L, PD-L1) modulates type 1 versus 
type 2 cytokine production and RSV pathogenesis in vivo286,287, but the function of other co-
stimulator/co-inhibitor in RSV infection are still unknown. Here we reported CTLA-4, OX40 and 
Lag3 are regulated by Dll4 in vitro in iTreg cells and in vivo during RSV infection. Systemic 
neutralization of Dll4 perturbed the percent of CTLA-4, OX-40 and Lag3 expression on Foxp3+ 
Treg (Appendix Figure A.2 and A.3). It will be intriguing to investigate the contribution of T 
cells’ co-stimulation/co-inhibitors in Notch/Dll4 regulated RSV immunopathology in the future.  
 
5.4.1 Notch and Dll4 support type 1 regulatory T cells (Treg1) marker—Lag3 
        Among all the co-inhibitors, Lag3 may be the most interesting one because of the its important 
role in modulating T cell tolerance. In fact, Lag3 is a structural homolog of CD4, and it could bind 
to the MHC-II complex in a competitive manner. There is an inhibitory “KIEELE” domain to 
inhibit T cell receptor (TCR) activation and mediate Treg function in both Foxp3+ Treg cells and 
Foxp3- IL-10 producing type 1 T regulatory cells (Treg1)255,256,288. Here we found the novel 
regulation of Notch and Dll4 in Lag3. Lag3 is one of the top candidates in RNA-seq experiment 
with small p-value and high fold changes regulated by both Dll4 stimulation and SMYD3 deletion. 
Dll4 stimulation up-regulated Lag3 expression not just in iTreg differentiation assessed by RNA-
seq has shown but also in Th0, Th2, and Th17 (Figure A.3.A). And Lag3 expression was RBP-Jk 
canonical Notch dependent (Figure A.3.B). Dll4 enriched H3K4me3 at the Lag3 promoter, and 
the stimulation increased % Lag3+ cells in different Th (Figure A.3.C~D). In vivo, Lag3 
expression was up-regulated after RSV infection (Figure A.3.E), and Dll4 neutralization enriched 
the percent Lag3 + cells in T cells but not APC at 6 dpi in primary RSV infection (Figure A.3.F). 
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Although Lag3 were expressed on both CD8+CD3+ and CD4+CD3+ T cells, Dll4 neutralization 
only enriched % Lag3+ on CD4 T cells, both Foxp3+ Treg and Foxp3- Tconv (Figure A.3.G).  
On the other hand, Dll4 KD DC displayed decreased percentages of Lag3+ T cells in RSV re-
infection (Figure A.3.H). So far our current data suggest that Notch/Dll4 regulates Lag3 on CD4 
T cells, but the role of Dll4 on Lag3 is context-dependent. Future studies need be performed after 
overcoming the low binding efficacy of anti-Lag3 antibody with a new and better generation of 
monoclonal antibody that Merck and other companies are working on (personal conversation with 
Dr. Dan Cua at ICMI 2017). With better tools, we will be able to determine the precise role of 
Notch in Lag3 RSV pathogenesis and beyond.  
 
5.5 Redundancy of H3K4 methylase in Foxp3 and Treg cell regulation 
        Our research shows that Dll4-facilitated H3K4me3 on Foxp3 promoter and CSN elements 
was SMYD3-dependent (Figure 4.5C). One important observation is that Smyd3 gene deletion 
and Smyd3 inhibition don’t completely abrogate all H3K4me3 on all Foxp3 regulatory element 
(Figure 4.5C and Figure 4.8A). It is possible that other histone methyltransferases also contribute 
to the H3K4me3 around Foxp3 regulatory elements. Besides Smyd3, KMT2B (MLL4) is the only 
other histone methyltransferase that is reported to involve in Foxp3+ Treg development188. But the 
mechanism associated with MLL4 is not able to explain the residual H3K4me3 since MLL4 
mainly catalyzes H3K4 mono-methylation (H3K4me). It will be interesting to explore if other 
H3K4 tri-methylase are involved in Treg cell development and maintenance. Preliminary results 
from Drs. Kunkel and Schaller indicates that another H3K4 tri-methylase, namaely MLL1, could 
potentially regulate Foxp3+ Treg development in vivo and maintain immune tolerance from 
inflammatory bowel phenotype (unpublished data in Schaller lab). Future studies will be 
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performed to elucidate other methyltransferase in Treg and immune tolerance in mucosal surface 
(e.g. lung, gut, skin).  
 
5.6 SMYD3 may also function as a protein methylase that regulates histone sites other than 
H3K4  
        One caveat about SMYD3 function is that SMYD3 is not only a H3K4 di- and tri-methylase 
but also a H4K20 methylase as well as protein methylase 191,245. Therefore, it is likely that 
Dll4/Notch-driven Smyd3 not only regulates Foxp3+ Treg cell differentiation through H3K4 
trimethylation on Foxp3, but may also have broad effects on gene expression and possibly protein 
function, as indicated by our RNA-seq analysis demonstrating a diverse set of genes altered in 
Smyd3 deficient Treg cells. For example, Il10 expression is supported by both Dll4 and Smyd3 in 
vitro in iTreg cells and in vivo during RSV infection. Unlike the Foxp3 results shown in Figure 
4.5C that H3K4me3 around Foxp3 locus are Smyd3-dependent, we didn’t detect abrogation of 
H3K4me3 on Il10 promoter in Smyd3-deleted iTreg cells. Another example is Lag3. Our RNA-
seq results and data in Appendix Figure A.3 highlight the strong influence of Dll4/Notch in Lag3 
gene expression, while Smyd3 cKO have decreased Lag3 expression. But again we can’t detect a 
decrease of H3K4me3 on the Lag3 promoter in Smyd3-deleted iTreg cells (data not shown). These 
negative result suggest an alternative  function or an indirect effect of Smyd3 in Il10 and Lag3 
regulation.  Future studies need to further investigate the mechanism of how Smyd3 affects the 
anti-inflammatory cytokine, IL-10 and the Treg1 marker, Lag3 in CD4 T cells for more precise 
regulation of tolerance. 
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5.7 SMYD3 modulates CD4 tolerance at another mucosal surface: gut  
        SMYD3 deletion supports tolerogenic CD4 T cells including Foxp3+ Treg cells and IL-10 
production in pulmonary infection. We are also curious if these phenotypes exist in a steady state 
without inflammation or infection. We had investigated the Treg in thymus and periphery and 
found no significant differences in Treg development in unmanipulated SPF mice (data not 
shown) . SMYD3 Cre+ KO mice have a similar number and percent of Foxp3+ CD4 T cells in the 
thymus compared to wildtype mice (Figure A.4.A). Unlike the phenotype in Foxp3 scurfy mice 
and Foxp3 depleted mice, Smyd3-deleted mice have no splenomegaly, lymphomegaly or other 
autoimmunity disease (Figure A.4.B). Treg cell development in the spleen was slightly 
compromised (Figure A.4.C), and Foxp3-inhibited cytokines, namely IL-4, IL-5, IL-13 and IL-
17A, were up-regulated after 24 hours of T cells activation with P + I (Figure A.4.D). These data 
suggest that Smyd3 deletion in CD4 T cells has a minimal effect in SLO. Since Dll4 is highly 
expressed on lacteal lymphatic vessels in gut lamina propria289, and multiple cell types (eg., 
epithelial cells, gut dendritic cells, Treg cells) in the gut lamina propria express TGF-b290,291. More 
recently, CD103+ DC in gut lamina propria were shown to participate in TGF-b mediated 
induction of pTreg cells292,293. Here we isolated colon lamina propria lymphocyte(LPL) that is 
enriched with IL-10 producing and Foxp3+ Treg cells126,132. CD4-specific Smyd3 knockout mice 
have significantly fewer Foxp3+ Treg in colon LPL in 6 to 7 weeks old adult mice compared to 
wt control mice (Figure A.4.E~F). Moreover, decreased percentages and numbers of Foxp3+ Treg 
cells were detected in 23-26 weeks old mice (data not shown). Meanwhile, Foxp3 expression in 
colon LPL was significantly decreased in 6-7 weeks old CD4-specific Smyd3 KO mice, as well as 
Il10 expression (Figure A.4.G~H). These data suggested that Smyd3 supported Foxp3 and Il10 
expression in vivo in the colon. Previous studies show that DC elicit IL-17A+ CD4 T cells and 
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Foxp3+ Treg cells in small intestine lamina propria292,294. Here we further investigate IL-17A and 
found that Smyd3 deletion enriched Il17a expression in LPL, and IL-17A+ CD4 T cells from small 
intestine lamina propria (Figure A.4.I-J). Thus, Smyd3 appears to be important for supporting 
Treg differentiation and stability in other mucosal sites like gut.  
 
5.8 SMYD3 may also regulate anti-tumor immunity in lung carcinoma model 
        Smyd3 can regulate multiple oncogenic pathways including RAS, Estrogen receptor, and E-
caderin-driven tumorogenesis to promote epithelial to mesenchymal transition (EMT) and be a 
transcription potentiator 199,200,245. Although Smyd3 promotes transformed cell growth and inhibits 
apoptosis as a cancer potentiator 193,194,199,295, we didn’t find that Smyd3 affected non-transformed 
CD4 T cell proliferation in CFSE-labeling experiment with iTreg cell differentiation (data not 
shown).  
        Due to the correlation of Smyd3 expression with poor prognosis in multiple cancers including 
colorectal carcinoma, breast cancer, hepatocellular carcinoma (HCC), lung adenocarcinoma, and 
pancreatic cancer193–198,245, the question remains whether Smyd3 in immune compartment may 
have a role in cancer progression. . In particular, our hypothesis was that overexpression of Smyd3 
in T cells may provide a repressive immune environment that allows the tumor to grow in an 
immunosuppressed environment.  To investigate if Smyd3 cells plays a role in CD4 T not only in 
lung infection but also in anti-tumor immunity against lung carcinoma, we collaborated with Peter 
Chockley and Dr. Venkat Keshamouni to subcutaneously inject Lewis lung carcinoma (LLC) cells 
under the two lateral back of Cre- control or Cre+ Smyd3 cKO mice. Surprisingly, CD4-specific 
Smyd3 KO that have impaired Smyd3 expression in both CD4 and CD8 T cells had more LLC 
tumor lung metastasis than control (Figure A.4.A). The metastatic lungs had higher pro-metastatic 
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cytokine Il22 with no increase in Il17a, Il10, and Tgfb in Smyd3 KO mice (Figure A.5.B), 
indicating a potential role of IL-22 in LLC metastasis. The percent and number of Foxp3+ Treg 
cells in draining inguinal LN were decreased (Figure A.4.C) as we had observed in other models. 
In sorted CD4 and CD8 T cells, there was less Il2 in CD4 and less Ifng in CD8 T cells (Figure 
A.4.D). While Smyd3 cKO mice again had fewer Foxp3+ Treg cells compared to control mice, 
our data did not find more Ifng in CD8 T cells in Smyd3 cKO, a result that challenges the paradigm 
of Treg cells as inhibitors of anti-tumor cytotoxicity.  Instead, Less Ifng from CD8 T cells and 
more Il22 from CD4 T cells were observed to support more LLC lung metastasis. These results 
strongly suggest that Smyd3 in T cells regulate LLC metastasis, and the consequence of not having 
Smyd3 during tumorigenesis appears to be detrimental due to other effects of the Smyd3 regulation 
on the immune responses.  Thus, our understanding of Smyd3 can not be generalized and need to 
be further defined.  
        Together, the data presented in my dissertation addresses new and exciting findings that 
demonstrate a conserved pathway, Notch, that epigenetically promotes Foxp3+ Treg cell 
differentiation through SMYD3 and harnesses Treg tolerogenic identities (e.g. IL-10, Lag3) to 
dampen immunopathogenesis in pulmonary viral infection.  Furthermore, current thesis also open 
up new and excited questions to be tested in the future.  
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Appendix 
Additional observations of Dll4 and SMYD3 in regulatory T cells 
 
 
Figure A.1 Dll4 neutralization decreases Nrp1- adaptively induced Treg (iTreg) in RSV 
infection 
Balb/c mice were intratracheally infected with Line19 RSV, and Dll4 were neutralized by 
anti-Dll4 antibody every other day (same experimental procedure as described in Chapter 
3.3.2). Splenic Foxp3+ CD4 T cells (Foxp3+CD4+CD3+LD-) were stained with Neuropilin-
1 (Nrp1) antibody that is a marker of tTreg but not iTreg. Nrp1- iTreg were gated at 6 dpi and 
8 dpi after Dll4 neutralization.  
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired two-tailed 
t-test)  
 
 
 
Figure A.2: Co-inhibitor CTLA-4 and co-stimulator OX40 are differentially regulated by 
Dll4 neutralization in RSV infection 
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Balb/c mice were intratracheally infected with Line19 RSV, and Dll4 were neutralized by 
anti-Dll4 antibody every other day (same experimental procedure as described in Chapter 
3.3.2). At 8 dpi, Foxp3+ CD4 T cells (Foxp3+CD4+CD3+LD-)  in lung and mediastinal 
lymph node (mLN) were stained with intracellular CTLA-4 and extracellular OX-40 
antibody that are both functional marker of Treg.  
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired two-tailed 
t-test)  
 
Figure A.3: TCR co-inhibitor Lag3 is dependent on Dll4 and intracellular Notch signaling 
in vivo and in vitro 
A. Naïve CD4 T cells were isolated from Cre- control B6 mice and skewed toward Th0, 
Th2, Th17, and iTreg with or without Dll4 stimulation. After 48 hours, Lag3 mRNA 
were measured.  
B. Naïve CD4 T cells were isolated from wt control or CD4-specific Rbpj KO mice, and 
skewed toward iTreg with or without Dll4 stimulation. After 24 hours, Lag3 mRNA 
were measured.  
C. Naïve CD4 T cells were isolated from Cre- control B6 mice and skewed toward iTreg 
with or without Dll4 stimulation. After 72 hours, chromatin and DNA were 
crosslinked and H3K4me3 were immunoprecipitated. Lag3 promoter were then PCR 
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to quantified the H3K4me3 modification on Lag3 promoter with or without Dll4 
stimulation. 
D. Naïve CD4 T cells were isolated from Cre- control B6 mice and skewed toward Th0, 
iTreg and type 1 Treg (Tr1 here were skewed in IL-27 20ng/mL and TGF-b 2 ng/mL 
here) with or without Dll4 stimulation. After 72 hours, Lag3 protein on CD4 T cells 
surface were stained and quantified by flow cytometry. 
E. Balb/c mice were intratracheally infected with RSV Line19. After 4 days post 
infection (dpi) and 6 dpi, lung were harvest and Lag3 expression were measured. 
F. Balb/c mice were intratracheally infected with RSV Line19, and Dll4 were neutralized 
by anti-Dll4 antibody every other day. At 6 dpi, Lung T cells (CD3+MHCII-) and 
APC (MHCII+CD3-) were gated. Lag3 on T cells or APC were stained.  
G. Naïve CD4 T cells from Cre- control or Smyd3 cKO were differentiated to iTreg cells 
with or without Dll4 for 48 hours. Il17a mRNA was measured.  
H. UBC-Cre/ERT2 mice were bred with Dll4F/F mice to have inducible Dll4 knockdown 
mice on C57BL6 background. After taking bone marrow and culture into DC for 6 
days, these BMDC were incubated with 1 mM 4-OHT for 48 hours to knockdown 
(KD) Dll4. After infected with RSV MOI=0.5 for 24 hours, control or Dll4-KD RSV-
infected BMDC were intratracheally transferred into same recipient of Foxp3eGFP 
mice. After 12 days, both wt BMDC and Dll4 KD BMDC transferred recipients were 
rechallenged with RSV infection. After another 8 days, CD4 T cells in lung were 
harvest and Lag3 on CD4 T cells were stained. 
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired two-tailed 
t-test)  
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Figure A.4: SMYD3 in T cells maintains gut immune tolerance in un-manipulated SPF 
mice  
A. 5~6 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed, and the number of thymic Treg (CD4+CD8-Foxp3+) were 
measured.  
B. 19 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. The size of spleen, inguinal lymph node, axillary lymph node, 
and cervical lymph node were compared. 
C. 16~19 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout 
(Smyd3 cKO) were sacrificed. Number of splenic peripheral Treg 
(CD3+CD4+Foxp3+) were measured. 
D. 23~26 week old splenocytes were re-stimulated with PMA+Ionomycin without Golgi 
Stop and Golgi plug for 24 hours. T cells cytokines in supernatant were measured.  
E. 26 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. Colon were longitudinally opened, fixed and rolled. Cross 
section of colon were stained by H&E to visualize histopathology of colon 
inflammation. 
F. 6 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. Colon lamina propria lymphocytes (C-LPL) were enriched, and 
Foxp3+CD4+CD3+ Treg were stained and counted.  
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G. 6 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. Colon lamina propria lymphocytes were enriched, and Foxp3 
expression in C-LPL were measured. N=4 in each group 
H. 6 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. Colon lamina propria lymphocytes were enriched, and Il10 
expression in C-LPL were measured. N=4 in each group 
I. 6 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. Small intestine lamina propria lymphocytes were enriched, and 
Il17a expression in SI-LPL were measured. N=4 in each group 
J. 17 week old Cre- littermate control and Cre+ CD4-specific Smyd3 knockout (Smyd3 
cKO) were sacrificed. Small intestine lamina propria lymphocytes were enriched, and 
Il17a expression in SI-LPL were measured. 
Data represent mean ± SEM. Data were from one experiment representative of two to three 
experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired two-tailed 
t-test)  
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Figure A.5: SMYD3 in T cells limits lung cancer metastasis and anti-tumor immunity in 
vivo 
A. 106 Lewis lung carcinoma (LLC) were subcutaneously injected into the left and right 
flank of Cre- littermate control and Cre+ Smyd3 cKO. LLC proliferated and the size of 
local LLC were measured. Mice were sacrificed at day 21, and the number of LLC 
metastatic nodule in lung were counted.  
B. At day 21 of LLC transfer, Cre- littermate control and Cre+ Smyd3 cKO mice were 
sacrificed, and Il17a, Il10, Il22, and Tgfb expression in metastatic lung were measured.   
C. At day 21 of LLC transfer, the draining lymph node—inguinal lymph node (iLN)—
were harvest. The percent and number of CD3+CD4+Foxp3+ Treg were gated and 
measured in Cre- littermate control and Cre+ Smyd3 cKO.  
D. At day 21 of LLC transfer, CD4 T cells and CD8 T cells in iLN were sorted. The 
expression of Ifng in CD8 T cells and Il2 in CD4 T cells were measured in either LLC 
transfer Cre-/Cre+ or un-transferred naïve Cre-/Cre+.  
Data represent mean ± SEM. Data were from one experiment representative of two to 
three experiments. * P<0.05; ** P<0.005; *** P<0.0005; NS: no significance (unpaired 
two-tailed t-test)  
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